CANADIAN NEUROLOGICAL SCIENCES FEDERATION

FÉDÉRATION DES SCIENCES NEUROLOGIQUES DU CANADA

Photo courtesy of Gary Woodburn - http://pbase.com/woody

43rd Annual Congress of the

Canadian Neurological Sciences Federation

Victoria, British Columbia

June 17-20, 2008

final program

Secondary Stroke Prevention:
Where Have We Been and Where Are We Going?

Satellite Symposium

Wednesday, June 18, 2008 • 12:30 pm – 2:00 pm
The Fairmont Empress • Crystal Ballroom
Victoria, British Columbia

Program Faculty

Program Chair
Mukul Sharma, MD, MSc, FRCPC
Assistant Professor of Medicine
University of Ottawa
Deputy Director, Canadian Stroke Network
Director, Champlain Regional Stroke Program
The Ottawa Hospital
Ottawa, Ontario

Sylvain Lanthier, MD, OD, CSPQ
Stroke Neurologist
Cerebrovascular Disease Centre
Division of Neurology
Centre hospitalier de l'Université de Montréal (CHUM)
Adjunct Professor
Université de Montréal
Montreal, Quebec

Frank L. Silver, MD, FRCPC
Professor of Medicine, Neurology
University of Toronto
Director, Toronto West Stroke Region
Toronto Western Hospital
Toronto, Ontario

Gregory W. Albers, MD
Coyote Foundation Professor
Stanford University
Director, Stanford Stroke Center
Stanford University Medical Center
Stanford, California

Philip Teal, MD, FRCPC
Professor of Neurology
University of British Columbia
Director, Vancouver Hospital Stroke Program
Vancouver General Hospital
Vancouver, British Columbia

This program has been reviewed and co-developed by

Canadian Neurological Society / Société canadienne de neurologie

Boehringer Ingelheim

This event is an accredited group learning activity (Section I) as defined by the Maintenance of Certification (MOC) program of the Royal College of Physicians and Surgeons of Canada. It is co-developed by the Canadian Neurological Society and Boehringer Ingelheim (Canada) Ltd. This program has been reviewed and approved for one Level 1 credit by the Canadian Neurological Society.

Scientific Program Chair Mike Tymianski, Vice Chairs Michael Hill and John Stewart, their Committee members (listed below), the CNSF Board and staff welcome you to the 43rd Congress of the Canadian Neurological Sciences Federation.

We are confident you will enjoy the Program this year. We have incorporated many exciting changes to the Congress in our continuing effort to provide our delegates the most comprehensive meeting of neurologists, neurosurgeons and neuroscientists in the country.

Based on last year's Congress Evaluation and the CNSF Member Survey conducted in 2007, we have a number of new educational offerings at the Congress this year:

1. The Neurobiology Review Course on Tuesday has been organized by members of the Canadian Association for Neuroscience.
2. There is a new Neuroradiology Course, organized by the Neuroradiology community, that will sure to be of interest to delegates.
3. We are introducing a Course on Cerebrovascular Surgery that is being organized by Scientific Program Committee Chair, Dr. Mike Tymianski.
4. The popular Grand Rounds session will this year incorporate the use of a touchpad response system that is sure to make what is already a highly interactive session even more so.
5. Abstract submissions were the highest we've seen in years, so the Digital Poster stations will be quite busy. As well, the author standby tours have been re-conceptualized as "mini-platform sessions" so expect to see lively discussion in those sessions.
6. Also anticipate more Digital Poster stations, more Congress Course Notes printing stations and the same exciting Plenary Lectures that you've come to expect; including our Special Guest Lecturer Dr. Dennis Choi.

During this Congress there will be opportunities for you to:

1. Network with colleagues, mentors and friends.
2. Rejuvenate your practice with additional knowledge and skill.
3. Stimulate your thinking.
4. Earn Section 1 MOC Credits.
5. Work on your personal learning needs.

We hope you find this Congress as educational, broad based, innovative, creative and exciting as we do.

Please tell us how we are doing by completing the Session Specific Evaluation Forms, which will be in the Course and other session rooms, and the Overall Congress Evaluation, available on line and in your registration portfolio. It is important that you provide us this feedback so we can continue to improve and better meet your learning needs.

Again, welcome and thank you.

Yours truly,

Andrew Kirk
President
CNSF



Mike Tymianski
Chair
Scientific Program Committee

Please visit the following web sites for further information on the Congress and the City of Victoria
www.cnsfederation.org www. victoria.ca

[illegible]

The Executive Committee oversees the affairs of the organization, making decisions on behalf of the Board between full board meetings and serves as a liaison between the Board and the Chief Executive Officer. The CNSF President, two Vice-Presidents, and Chief Executive Officer (non-voting) serve on the Executive Committee.

[illegible]

[illegible]

The Scientific Program Committee is responsible for planning all aspects of the scientific programs for the annual CNSF Congress, which is an accredited learning activity approved for Section I credits as defined by the Royal College of Physicians and Surgeons of Canada.
The committee oversees and coordinates: the Congress's educational courses, satellite symposia and workshops; abstract adjudication; program structure; policies regarding invited guests; and, short and long-term objectives and curricula.

[illegible]

[illegible]

[illegible]

The Victoria Conference Centre
720 Douglas Street
Victoria, BC V8W 3M7

[illegible]

[illegible] - Victoria Conference Centre

Tuesday, June 17	07:30 – 18:30
Wednesday, June 18	07:00 – 18:30
Thursday, June 19	07:00 – 18:30
Friday, June 20	07:00 – 13:30

[illegible]

June 9 – 12, 2009	Halifax, Nova Scotia
June 8 – 11, 2010	Quebec City, Quebec

[illegible]

[illegible]

- Full registrants can attend all sessions of the 2008 Annual Congress from Tuesday, June 17 through Friday, June 20.
- Includes the Exhibitors' Reception.

[illegible]

- One-day registrants can attend all sessions on that day. Also the Exhibitors' Reception on Wednesday, or lunch in the Exhibit Hall on Thursday or Friday, if you are registered on that day.

[illegible]

- Delegates must wear their badges at all times to gain entry to Congress Courses, Scientific Sessions and evening events. Tickets will be collected for the Presidents' Reception.

Victoria British Columbia

[illegible]

[illegible]

Tuesday, June 17, 2008 - 07:15-08:15
Victoria Conference Centre - All residents are invited to attend and to meet with their colleagues and CNSF Board members. Complimentary continental breakfast provided.

[illegible]

Wednesday, June 18, 2008 - 17:30-19:00
Victoria Conference Centre - Carson Hall
Wine & Cheese. Cash bar. [illegible]

[illegible]

Thursday, June 19, 2008 - 17:30-19:00
Victoria Conference Centre. Socialize with your friends and colleagues. Business casual. Hors d'oeuvres and two complimentary drink tickets then a cash bar. This is the main social event of the Congress, it is hors d'oeuvres only, it is not dinner and is not included with registration. All attendees must purchase tickets for $35.00, which will need to be presented at the door.

Educational Objectives for the 2008 Congress:

By the end of the Congress the participants will be able to:

1. Discuss the advances in the diagnosis and management of acute and chronic neurological diseases
2. Review new treatment options for neurosurgical illnesses
3. Summarize advances in the neurobiology of chronic pain
4. Describe challenges in the diagnosis and management of inborn errors of metabolism

General Meeting Information 2

Daily Events Calendar

- Scientific Sessions 4
- Social Events 4
- Business Meetings 6

Daily Scientific Sessions - Meetings at a Glance 8

Plenary Guest Speakers 10

Maintenance of Certification 12

- How to obtain CME credits

Meeting Level Map 13

Detailed Scientific Program

- Tuesday, June 17, 2008 15
- Wednesday, June 18, 2008 21
- Thursday, June 19, 2008 27
- Friday, June 20, 2008 28

Board Photos 34

Exhibition Hall and Booth Assignments 35

Winners of the 2008 Society Prizes 36

Platform Sessions 37

Poster Sessions 48

Accreditation FRCPC ou FRCSC 12

- Comment obtenir des crédits CME

Reseignements D’ordre Général 60

Programme des Activités 61

- Programme scientifique
- Réunion d’affaires
- Activités sociales

Programme Scientifique

- Mardi 17 juin 2008 64
- Mercredi 18 juin 2008 68
- Jeudi 19 juin 2008 72
- Vendredi 20 juin 2008 73

[illegible]

07:00-18:00 Speaker Centre
Metchosin Room, Conference Centre

07:15-08:15 Resident's Breakfast
Saanich Room, Conference Centre

07:30-18:30 Registration
Registration Area, Conference Centre

08:30-17:00 [illegible]
Lecture Theatre, Conference Centre

08:30-17:00 [illegible] *Oak Bay Room, Conference Centre*

08:30-17:00 [illegible]
Crystal Ballroom, Empress

12:15-13:00 ALS Lunch
Saanich Room, Conference Centre

18:00-20:00 [illegible]
Lecture Theatre, Conference Centre

18:00-20:00 [illegible]
Oak Bay Room, Conference Centre

W[illegible]

07:00-18:00 Speaker Centre
Metchosin Room, Conference Centre

07:00-18:30 Registration
Registration Area, Conference Centre

08:30-10:30 [illegible]
Lecture Theatre, Conference Centre

10:30-10:45 Break *Foyer, Conference Centre*

10:45-12:15 [illegible]
Lecture Theatre, Conference Centre

12:30-14:00 [illegible]
Co-developed *Crystal Ballroom, Empress*

12:30-14:00 [illegible]
Co-developed
Saanich Room, Conference Centre

14:00-17:30 [illegible]
Sidney Room, Conference Centre

14:00-17:30 [illegible]
Lecture Theatre, Conference Centre

14:00-17:30 [illegible]
Buckingham Room, Empress

14:00-17:30 [illegible]
Oak Bay 2, Conference Centre

14:00-17:30 [illegible]
Oak Bay 1, Conference Centre

14:00-17:30 [illegible]
Esquimalt Room, Conference Centre

17:30-19:00 Opening of Exhibits - Exhibitors' Reception
Carson Hall, Conference Centre

[illegible]

07:00-18:00 Speaker Centre
Metchosin Room, Conference Centre

07:30-18:30 Registration
Registration Area, Conference Centre

08:30-10:00 [illegible]
Lecture Theatre, Conference Centre

08:30-10:00 [illegible]
Saanich Room, Conference Centre

10:00-10:15 Break *Carson Hall, Conference Centre*

10:15-12:30 [illegible]
Lecture Theatre, Conference Centre

10:15-12:30 [illegible]
Sidney Room, Conference Centre

10:15-12:30 [illegible]
Oak Bay 1, Conference Centre

10:15-12:30 [illegible]
Oak Bay 2, Conference Centre

10:15-12:30 [illegible]
Esquimalt Room, Conference Centre

10:15-12:30 [illegible] *Saanich Room, Conference Centre*

[illegible]

10:15-12:30 ([illegible])
Colwood Room, Conference Centre

12:30-14:00 Lunch and Exhibit Viewing
Carson Hall, Conference Centre

12:30-14:00 [illegible]
Carson Hall, Conference Centre

14:00-16:30 ([illegible])
Lecture Theatre, Conference Centre

14:00-16:30 ([illegible])
Oak Bay 1, Conference Centre

14:00-16:30 ([illegible])
Saanich Room, Conference Centre

14:00-16:30 ([illegible])
Oak Bay 2, Conference Centre

14:00-16:30 ([illegible])
Esquimalt Room, Conference Centre

14:00-16:30 ([illegible])
Sidney Room, Conference Centre

14:00-16:30 ([illegible])
Colwood Room, Conference Centre

16:30-17:30 Digital Poster and Exhibit Viewing
Carson Hall, Conference Centre

17:30-19:00 Presidents' Reception
Courtyard, Conference Centre

[illegible]
Annual General Meeting (AGM)
Canadian Association of Child Neurology (CACN)
Canadian Neurological Sciences Federation (CNSF)
Canadian Journal of Neurological Sciences (Journal)
Canadian Neurological Society (CNS)
Canadian Neurosurgical Society (CNSS)
Canadian Society of Clinical Neurophysiologists (CSCN)
Neurological Sciences Foundation of Canada (NSFC)
Association of Electromyography Technologists of Canada (AETC)
Bold type shows scientific program events. Non-bold shows other events.

[illegible]

07:00-14:30 Speaker Centre
Metchosin Room, Conference Centre

07:00-13:30 Registration
Registration Area, Conference Centre

08:30-09:30 [illegible]
Lecture Theatre, Conference Centre

09:30-09:35 Journal Reviewer of the Year Award Presentation
Lecture Theatre, Conference Centre

09:35-09:45 Journal Report
Lecture Theatre, Conference Centre

09:45-10:15 Break / Digital Poster and Exhibit Viewing
Carson Hall, Conference Centre

10:15-12:00 [illegible]
Lecture Theatre, Conference Centre

12:00-13:30 Lunch and Exhibit Viewing
Carson Hall, Conference Centre

12:00-13:30 [illegible]
Carson Hall, Conference Centre

13:30-17:00 [illegible]
Saanich Room, Conference Centre

13:30-17:00 **W[illegible]K[illegible]**
Oak Bay, Conference Centre

13:30-17:00 [illegible]
Esquimalt Room, Conference Centre

13:30-17:00 [illegible]
Colwood Room, Conference Centre

13:30-17:00 [illegible]
Sidney Room Conference Centre

13:30-17:00 **W[illegible]K[illegible]**
Lecture Theatre, Conference Centre

13:30-17:00 [illegible]
Crystal Ballroom, Empress

See complete Poster listings on pages 48-59

[illegible]

11:00-12:00 CNSF Committee Meeting - Governance
Buckingham Room, Empress

12:00-15:00 CNSF Committee Meeting - Planning & Reporting
Buckingham Room, Empress

15:00-16:00 NSFC Board Meeting
Buckingham Room, Empress

16:00-17:00 CNSF Board Meeting
Buckingham Room, Empress

17:30-18:30 CACN Council Meeting
Kensington Room, Empress

17:30-19:00 CAN/CNSF 2010 Meeting
Buckingham Room, Empress

[illegible]

09:00-11:00 CNSF Professional Development Committee Meeting *Sidney Room, Conference Centre*

10:00-12:00 CNSF Scientific Program Committee Meeting
Sidney Room, Conference Centre

12:00-13:00 CSCN EMG Section Committee Meeting
Buckingham Room, Empress

12:00-13:30 Neurology Residents Meeting
View Royal Room, Conference Centre

13:00-14:00 CSCN EEG Committee Meeting
Buckingham Room, Empress

13:00-14:00 Journal Editorial Board Meeting
Balmoral Room, Empress

14:00-15:00 Journal Publications Committee Meeting
Buckingham Room, Empress

16:30-18:00 CSCN Council Meeting
Buckingham Room, Empress

16:30-18:00 CNSS Council Meeting
Balmoral Room, Empress

16:30-17:30 Neurosurgery Residents Business Meeting
Colwood 1, Conference Centre

17:00-18:00 CACN AGM *Crystal Ballroom, Empress*

18:00-20:00 Neuromuscular SIG Meeting
Saanich Room, Conference Centre

[illegible]

07:30-08:30 Canadian League Against Epilepsy - AGM

[illegible]

07:00-08:30 Canadian Board of Registration of EEG Technologists Meeting *Balmoral Room, Empress*

07:30-08:30 CNSF Affiliate Societies Meeting
Kensington Room, Empress

07:00-08:30 CNS Council Meeting *Windsor Room, Empress*

12:30-13:30 Canadian Neurocritical Care Society Meeting
Windsor Room, Empress

12:30-13:30 CNS Foundation Board Meeting
View Royal, Conference Centre

13:00-14:00 Canadian Pediatric Neurosurgical Study Group
Kensington Room, Empress

17:00-18:30 CNS AGM *Balmoral Room, Empress*

[illegible]

07:00-08:30 CSCN AGM *Sidney Room, Conference Centre*

07:00-08:30 CNSS AGM *Colwood Room, Conference Centre*

09:30-10:30 Canadian Brain & Nerve Health Coalition
View Royal, Conference Centre

10:30-12:00 Canadian Pediatric Neuromuscular Research Group
View Royal, Conference Centre

12:00-13:00 Canadian Neuromuscular Group Meeting
View Royal, Conference Centre

12:00-13:15 Canadian Headache Society AGM
Windsor Room, Empress

12:00-13:00 Royal College Committee Neurosurgery
Buckingham Room, Empress

17:00-18:00 CNSF & Associate Societies Board Meeting
View Royal, Conference Centre

17:00-22:00 Canadian Headache Society Guidelines Meeting
Windsor Room, Empress

CENTRAL NEUROPATHIC PAIN
Associated with
Common Neurological Conditions

LUNCHEON SYMPOSIUM

Wednesday, June 18, 2008 - 12:30 - 2:00 p.m.

Location: Victoria Conference Center, Saanich Room

Two different perspectives; from two specialists

Chair:
Dr. Allan Gordon
Neurologist

Presenter:
Dr. Martin Katzman
Psychiatrist

At the conclusion of this symposium, participants will be able to:

- Discuss causes and mechanisms of central neuropathic pain (CNeP)
- Debate evidence-based practice of CNeP management
- List the additional symptoms associated with the condition, such as anxiety and depression
- Explain why a comprehensive approach is necessary to treat CNeP (why "it takes more than a molecule").

A Paradigm of Pain

© 2008
Pfizer Canada Inc.
Kirkland, Québec
H9J 2M5

™Pfizer Inc, used under license

Pfizer
Working together for a healthier world™

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. It is co-developed by the Canadian Neurological Sciences Federation and Pfizer Canada. This program has been reviewed and approved for one Level 1 credit by the Canadian Neurological Society.

[illegible]

[illegible]

08:30-17:00
Neurobiology Review Course
[illegible]

08:30-17:00
ALS Strategies for Quality Life/Quality Care
[illegible]

08:30-17:00
Child Neurology Day
[illegible]

18:00-20:00
Epilepsy Video Session
[illegible]

18:00-20:00
Movement Disorders Course
[illegible]

W[illegible]

08:30-10:30
Grand Opening Plenary: Scientific and Technical Advances in the Clinical Neurosciences
[illegible]

10:45-12:15
Chair's Select Plenary Presentation
[illegible]

12:30-14:00
Stroke Satellite Symposium
[illegible]

12:30-14:00
Neuropathic Pain Satellite Symposium
[illegible]

14:00-17:30
Cerebrovascular Surgery Course
[illegible]

14:00-17:30
Spine Course
[illegible]

14:00-17:30
Neuroradiology Course
[illegible]

14:00-17:30
Stroke Course
[illegible]

14:00-17:30
Epilepsy Course
[illegible]

14:00-17:30
Neurocritical Care Course
[illegible]

[illegible]

08:30-10:00
Plenary Session: CNS, CACN and CSCN Neurology
[illegible]

08:30-10:00
Plenary Session: CNSS Neurosurgery
[illegible]

10:15-12:30
Platform Sessions (7 concurrent)
[illegible]

12:30-14:00
Digital Poster and Exhibit Viewing
[illegible]

14:00-16:30
Platform Sessions (7 concurrent)
[illegible]

16:30-18:00
Digital Poster and Exhibit Viewing
[illegible]

[illegible]

08:30-09:30
Distinguished Guest Lecturer
[illegible]

09:30-09:45
Reviewer Award Presentation and Journal Report
[illegible]

09:45-10:15
Digital Poster and Exhibit Viewing
[illegible]

10:15-12:00
Grand Rounds
[illegible]

12:00-13:30
Digital Poster and Exhibit Viewing
[illegible]

13:30-17:00
Headache Course
[illegible]

13:30-17:00
What's New in Neurosurgery?
[illegible]

13:30-17:00
EEG Course
[illegible]

13:30-17:00
Medical Legal Symposium
[illegible]

13:30-17:00
Dementia Course
[illegible]

13:30-17:00
What's New in Neurology?
[illegible]

13:30-17:00
Neuromuscular Course
[illegible]

The Canadian Neurological Sciences Federation is pleased to recognize our Sponsors* for 2008. These organizations partner with CNSF to determine the causes of, and develop treatment for diseases and injuries of the nervous system, and in the care of patients with these diseases and injuries. Along with support of the Canadian Journal of Neurological Sciences and other initiatives the CNSF maintains throughout the year, these organizations graciously provide unrestricted educational grants to the Annual Congress, this year in Victoria, British Columbia; June 17th – 20, 2008.

Diamond

Boehringer Ingelheim

Platinum

Pfizer

Gold

ucb

Silver

MERCK

sanofi aventis
Because health matters

Bristol-Myers Squibb Canada

Medtronic

Bronze

Talecris Biotherapeutics

Neurological Sciences Foundation of Canada

Canadian Neurological Society Foundation

Supporters

Lundbeck Canada
Stellate
Allergan

Codman Neuro/Johnson & Johnson
Roxon Medi-Tech
Teva Neuroscience
Boehringer/Lilly

IMRIS
Neurologica
Bayer Healthcare

* as of May 2,, 2008

W□□□□□□□□,□□□□□□

After Princeton, Dr. Blume graduated in medicine from McGill in 1962. He trained in paediatric and adult neurology, adult and child electroencephalography (EEG), and neonatal EEG in: Quebec, Montreal, Wisconsin, Mayo Clinic and Paris. Following two years as an Associate Consultant at Mayo, he joined the burgeoning Department of Clinical Neurological Sciences at the University of Western Ontario in 1972 under Drs. HJM Barnett and CG Drake. With Dr. John Girvin, he co-founded and co-directed the Epilepsy Programme at UWO/University Hospital where he is presently Professor Emeritus. Dr. Blume has served as president of the following professional societies: Canadian League Against Epilepsy (founding member), Canadian Society of Clinical Neurophysiologists, Canadian Association of Child Neurology, Canadian Board of EEG Technologists, American Clinical Neurophysiology Society and the Central EEG Society. He initiated and first-chaired the CSCN EEG examination. For the International League Against Epilepsy, Dr. Blume chaired the Committee on Glossary of Descriptive Terminology for Ictal Semiology and has been a member of the Seizure Classification Committee. He has received the following awards: The Wilder Penfield Award of the CLAE; The Commemorative Medal for the Queen's Golden Jubilee; and the HOPE (Helping Out People with Epilepsy) award of the Epilepsy London Support Group. Dr. Blume has served on the editorial board of the following neuroscience journals: The Canadian Journal of Neurological Sciences, Electroencephalography and Clinical Neurophysiology, European Neurology, Journal of Clinical Neurophysiology, International Abstracts, and Epilepsy Currents (American Epilepsy Society). Throughout his career, he lectured around the world including (Lennox Lecture of the AES/CLAE, Goldring Lecture of Washington University of St. Louis. With over 200 articles and chapters, Dr. Blume continues his interest in clinical neuroscience.

□□□□□□□□%.□□□?□□

Dr. Antoine Hakim was first an engineer and at the age of 29 began his medical training at The Albany Medical College in New York. In 1979 he completed his residency in Neurology at the Montreal Neurological Institute at which time his research career in stroke began.

Dr. Hakim's research interests have included: the study of selective cerebral vulnerability in stroke and other conditions, the determination of conditions for neuroprotection against ischemic damage, and investigation of post-stroke plasticity and means of enhancing it.

He has experience in the private, academic and hospital sectors, and has chaired and served as a member of many committees and boards of granting agencies, foundations, hospitals and professional associations. In addition to teaching, research, and administrative duties, he maintains clinical duties as a neurologist at The Ottawa Hospital. He has received many honours during his career, including the Jonathan Ballon Award in 1985, Researcher of the Year in Ottawa Award in 1995, Award of Excellence by the Canadian Stroke Consortium in 2000, and the Ottawa Life Sciences Council Career Achievement Award in 2004. In 2005 the Canadian Stroke Network was renewed by the Networks of Centres of Excellence Program for another four years with funding of $25.6 Million. In February 2007, he was honoured to receive the Thomas Willis Award, a Lifetime Achievement Award from the American Stroke Associated and delivered the Thomas Willis Lecture at the International Stroke Conference in San Francisco. He was appointed Officer of the Order of Canada in 2007 and received the MEDEC Award for Medical Achievement from Canada's Medical Device Technology Companies.

Dr. Hakim continues to support scientific discovery in stroke and its application to improve stroke prevention, care and rehabilitation. This is all only possible because of the commitment, dedication and support he obtains from many individuals and organizations at the University of Ottawa, at the Canadian Stroke Network, the Centre for Stroke Recovery, and during the many initiatives of the Canadian Stroke Strategy.

□□□□□□□□□□

Dennis Choi received the MD degree from the Harvard-MIT Health Sciences & Technology Program, as well as a PhD degree in Pharmacology and neurology residency/fellowship training from Harvard, before joining the faculty at Stanford in 1983. In 1991, he went to St. Louis to be the Jones Professor and Head of Neurology at Washington University, Neurologist-in-Chief at Barnes-Jewish Hospital, and Director of the McDonnell Center for Cellular and Molecular Neurobiology and the Center for the Study of Nervous System Injury. At the end of 2001 he joined Merck Research Labs as Executive Vice-President for Neuroscience, leaving in 2006 to accept appointments at Boston University as Professor of Pharmacology and Experimental Therapeutics, and at Oxford University as Visiting Professor in Clinical Neuroscience. In 2007 he joined Emory University as Executive Director of the university's Neuroscience Initiative. He is currently a member of the Institute of Medicine and its Neuroscience Forum, the Executive Committee of the Dana Alliance for Brain Research, and the visiting committee advising the Harvard-MIT HST Program. Past service has included the National Academy of Science's Board on Life Sciences, multiple editorial boards (including the Board of Reviewing Editors for Science, and founding co-editorship of Neurobiology of Disease) and advisory boards, presidency of the Society for Neuroscience, chairmanship of the US National Committee to the International Brain Research Organization, and vice-presidency of the American Neurological Association. His research on mechanisms of brain or spinal cord injury has been recognized by several awards.

□□K□□□□%.□K□□□

Edward M. Kaye, M.D. is currently Group V.P. of Clinical Research at Genzyme Corporation where he supervises the clinical research in the lysosomal storage disease programs and in the genetic neurological disorders. He received his medical school education and pediatric training at Loyola University Stritch School of Medicine and University Hospital, Child Neurology training at the Boston City Hospital, Boston University, and completed his training as a Neurochemical Research Fellow (Geriatric Fellow) at the Bedford VA Hospital, Boston University in 1983. He was head of the section of Neurometabolism, Pediatric Neurology at The Floating Hospital for Children (Tufts University) and research fellow in gene therapy at the Massachusetts General Hospital until 1996 when he moved to Philadelphia to become Chief of Pediatric Neurology and Director of the Barnett Mitochondrial Laboratory at St. Christopher's Hospital for Children. In 1998, he accepted the appointment as Chief of Biochemical Genetics at the Children's Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics until moving to Genzyme Corporation at the end of 2001. He continues as a member of the Neurology Department at the Children's Hospital of Boston and has been on the editorial boards of a number of journals including Annals of Neurology, Journal of Child Neurology, and Pediatric Neurology. He is also on the Medical Advisory Boards of the United Leukodystrophy Foundation and Spina Muscular Atrophy Foundation.

[illegible]

Dr. Mohr is from Lynchburg, Virginia, graduated from Haverford College in 1958, and from the University of Virginia in Charlottesville in 1963 with an M.D. and M.S. in Pharmacology as a USPHS five-year plan fellow.

He was an Intern and Medical Resident at the Mary Imogene Bassett Hospital in Cooperstown NY from 1962-1965. He began his residency training in Neurology with one year at the New York Neurological Institute at Columbia-Presbyterian Medical Center in New York City, and finished in 1969 at the Massachusetts General Hospital in Boston, where he also trained in Neuropathology and Stroke under C.M. Fisher, M.D. After three years Army service during the Viet Nam war at Walter Reed Army Institute of Research he returned to Boston in 1971 as an Assistant Professor of Neurology at Harvard Medical School to direct the Behavior Laboratory and Stroke Service at the Massachusetts General Hospital and as Director of the Neurology Unit at the Massachusetts Rehabilitation Hospital. In 1978 he became founding chairman of the Department of Neurology, University of South Alabama in Mobile.

In 1983 he returned to New York to became the Sciarra Professor of Clinical Neurology and Director fo Stroke research, which decveloped into the recently-estabished Doris & Stanley Tananbaum Stroke Center, Horace W. Goldsmith Neurovascular Laboratory and James M. Nederlander Teaching Unit at the Neurological Institute.

He serves on national and international committees and consulting boards, is editor of three books, 250 refereed and 105 invited publications.

[illegible]



Dr. Tator is a professor in the Department of Surgery, at the University of Toronto, and a neurosurgeon at the Toronto Western Hospital. After graduating from the Faculty of Medicine at the University of Toronto in 1961, he trained in research in neuropathology at the University of Toronto and received an MA in 1963 and a PHD in 1965. He completed the Neurosurgery resident training program at the University of Toronto in 1969. He has been Chair of Neurosurgery at the University of Toronto and the Chief of Neurosurgery at Sunnybrook and the Toronto Western Hospitals. He started the first Acute Spinal Cord Injury (SCI) unit in Canada in 1974, and studied the epidemiology, prevention and treatment of acute SCI. He examined the role of surgery and acute spinal cord decompression in clinical and experimental studies.

His laboratory research has been aimed at determining the pathophysiology of SCI, especially mechanisms of secondary injury including posttraumatic ischemia. His acute cord clip compression model was the first SCI model in rodents. His current laboratory focus is on stem cell research for regeneration after spinal cord injury.

He has held two research chairs at the University of Toronto, the Dan Family Chair in Neurosurgery and the Campeau Family-Charles Tator Chair in Brain and Spinal Cord Research. In 2000, he received the Order of Canada.

In 1985-86, he was President of the Canadian Neurosurgical Society, and from 2002-2007 he was Chair of the Canadian Brain and Nerve Health Coalition. In 1992, he founded ThinkFirst, Canada, a national brain and spinal cord injury foundation whose mission is to reduce the incidence of catastrophic injuries in Canada. He was President of ThinkFirst from 1992-2007. ThinkFirst is a leader in the promotion of safety for Canada's children and youth and has developed and disseminated targeted injury prevention programs in schools and in sports and recreation.

[illegible]

Dr. Garnette Sutherland received his undergraduate education in both science and medicine at the University of Manitoba, Winnipeg, Manitoba. His post graduate education was completed in 1984 at the University of Western Ontario, London, Ontario. He was appointed Assistant Professor of Surgery (Neurosurgery) and Pharmacology at the University of Manitoba and promoted to Associate Professor at the same university in 1988. In 1993, he accepted the position of Professor and Head of Neurosurgery - Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta and was Head until 2003. He has made a number of contributions to science and medicine, as reflected by 175 abstracts, 146 peer-reviewed publications, 18 monographs or book chapters, and 13 patents. His major research focus has been the application of MR techniques to the study of neurological diseases. Over the past 6 years he has lead Project neuroArm in the development of an MR-compatible image guided robotic system for neurosurgery. Dr. Sutherland was the founding Director of the Seaman Family MR Research Centre. In 2004, he received the Manning Award of Distinction for the development of an intraoperative MR system based on a movable 1.5 Tesla magnet and in 2007 he received the Federal Partners in Technology Transfer Award for Excellence in Technology Transfer and the ASTech Award for Outstanding Leadership in Alberta Technology.

[illegible]

Dr. Peter Rieckmann has recently arrived in Vancouver, Canada as the new Multiple Sclerosis Society of Canada Research Chair based at Vancouver Coastal Health (VCH) Research Institute's Brain Research Centre at UBC Hospital. He also holds positions as professor of neurology (Faculty of Medicine UBC) and director of the MS Program for UBC and VCH.

Dr. Rieckmann moved from Würzburg, Germany where he was head of the Clinical Research Group for MS and Neuroimmunology at the Julius-Maximilians University for the last 8 years. He studied and trained neurology and basic sciences at the university of Göttingen (Germany), National Hospital Queen Square, London UK and the National Institutes of Health, Bethesda USA. His major research interests are disease modifying factors and development of new therapeutic strategies to enhance tissue repair in multiple sclerosis. He has also worked on molecular and functional aspects of the blood brain barrier in neuroimmunological diseases.

His clinical goals include enhancing awareness and education about MS, developing new sensitive clinical scales as well as effective and properly resourced services for MS outpatient care leading to more customized treatments for patients.

Dr. Rieckmann holds a number of academic positions including visiting professorships at the University of Nagoya (Japan) medical university school of Belgrade (Serbia) and the University Medical School of Chennai in India. He is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC).

He has been presented with several honours, awards and prizes including the Hans-Heinrich-Queckenstedt-Prize, the Käte-Hammersen-Prize and the Langheinrich-Prize for MS Research. He sits on various boards including the Medical Advisory board of the Multiple Sclerosis International Federation, European Council for Treatment and Research in MS (ECTRIMS) and the international Multiple Sclerosis Therapy Consensus Group (MSTCG).

Dr. Rieckmann has produced over 150 original articles in peer reviewed journals, 58 review articles, 25 book chapters, 2 textbooks and has given more than 200 invited lectures.

He is married with two children.

%

The 43rd Annual Congress of the Canadian Neurological Sciences Federation is an accredited learning activity approved by the CNS and the CNSS, as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The Royal College of Physicians and Surgeons of Canada established the Maintenance of Certification program on January 1, 2001. Participation in this program is a requirement for admission to and renewal of Fellowship and for the use of the designations FRCPC and FRCSC.

The 2008 Congress has been approved for Section 1 under the Maintenance of Certification program. This means each attendee is assigned one credit per hour in education sessions. Breaks, lunch, and the poster sessions are excluded.

As Fellows are responsible for keeping track of their hours of participation in educational activities, they should keep a copy of this meeting program and their registration form for future reference. Certificate of Attendance Forms will only be issued once you have completed the Overall Congress Evaluation on line through a link we will be providing to all delegates, or completed the hard copy we will have in the delegates portfolio distributed at the Congress and faxed it to the CNSF Secretariat at 1-403-229-1661. The deadline for completion and submission is June 30th, 2008.

For more information about the Maintenance of Certification Program, please refer to the Royal College website http://www.rcpsc.medical.org or e-mail the CNSF secretariat office at info@cnsfederation.org

---

Le 43è congrès annuel de la Fédération des sciences neurologiques du Canada est une activité éducative agréée, approuvée par la SNC et la SCNCH selon la définition du programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada.

Le Collège royal des médecins et chirurgiens du Canada a institué le maintien du certificat le 1er janvier 2001.

Participer à ce programme est obligatoire pour l'obtention ou le renouvellement du titre d'Associé et pour utiliser les mentions FRCPC et FRCSC.

Le congrès 2008 a été approuvé comme activité de la Section 1 du programme de maintien du certificat. Ce qui veut dire que chaque participant reçoit un crédit pour chaque heure de séance éducative. Les pauses, les déjeuners et les présentations affichées n'en font pas partie.

Comme c'est la responsabilité des Associés de tenir une comptabilité de leurs heures de participation aux activités de formation, ils doivent garder une copie du programme de ce congrès et le formulaire d'inscription en vue d'une utilisation ultérieure. Des atestations d'assiduité ne vous seront délivrées que lorsque vous aurez rempli en ligne l'évaluation générale du congrès en utilisant un lien que nous indiquerons à tous les délégués, ou bien lorsque vous aurez rempli la feuille que vous trouverez dans le cartable distribué à tous les délégués au congrès et que vous l'aurez envoyée par télécopie au secrétariat de la FSNC au 1-403-229-1661. Date-limite pour remplir et soumettre l'évaluation: 30 juin 2008.

Pour plus de renseignements sur le programme de maintien du certificat, veuillez consulter le site web du Collège royal à http://www.rcpsc.medical.org ou envoyer un courriel au secrétariat de la FSNC à info@cnsfederation.org

%

Breaks, lunch and poster sessions are excluded

Date: Tuesday, June 17, 2008	
Neurobiology Review Course	6.5
ALS Strategies for Quality of Life/Quality Care	4.5
Child Neurology Day	6.5
Epilepsy Video Session	2.0
Movement Disorders Course	2.0
Date: Wednesday, June 18, 2008	
Grand Opening Plenary: Scientific and Technical Advances in the Clinical Neurosciences	2.0
Chair's Select Plenary Presentation	1.5
Stroke Satellite Symposium	1.5
Neuropathic Pain Satellite Symposium	1.5
Cerebrovascular Surgery Course	3.5
Spine Course	3.5
Neuroradiology Course	3.0
Stroke Course	3.0
Neurocritical Care Course	3.0
Epilepsy Course	3.0
Date: Thursday, June 19, 2008	
Plenary Session: CNS, CACN and CSCN Neurology	1.5
Plenary Session: CNSS Neurosurgery	1.5
Platform Sessions - Morning	2.0
Platform Sessions - Afternoon	2.5
Date: Friday, June 20, 2008	
Distinguished Guest Lecturer	1.0
Grand Rounds	1.5
Headache Course	3.0
What's New in Neurosurgery Course	3.5
EEG Course	3.5
Dementia Course	3.0
Medical Legal Symposium	3.0
What's New in Neurology	3.0
Neuromuscular Course	3.0
Total CME Hours	**79.0**

Victoria Conference Centre and Fairmont Empress





Victoria British Columbia

We see change.

UCBeyond™

Introducing UCB Pharma Canada, part of a leading global biopharmaceutical company with operations in more than 40 countries and over 12,000 employees worldwide.

In the past…

UCB scientists have developed leading allergy and epilepsy products.

In the present…

UCB research is developing next-generation Neurology products for the treatment of Parkinson's Disease, Restless Leg Syndrome, Diabetic Neuropathic Pain and Epilepsy.

In the future…

UCB R&D is forging ahead with new breakthroughs in the areas of Immunology, Neurology, Endocrinology and Oncology.

We see change. UCBeyond™

UCBeyond™ is a trademark of UCB, Inc. or its affiliates. © 2007 UCB S.A. All rights reserved. GPSRC INF 34 PROM TA 0506 CERTO

[illegible] 08:30-17:00 *(Lecture Theatre, Conference Centre)*

Course generously supported through an unrestricted educational grant from Boehringer-Ingelheim/Eli Lilly and the Canadian Neurological Society Foundation

[illegible] Peter Smith

[illegible] The course will focus on chronic pain. Faculty will use this as a framework to review various aspects of neurophysiology, neuropharmacology and neuroanatomy. We seek to provide "bench to bedside" information in a context relevant to clinical practice. We aim to show how pain management procedures work and why some are not universally effective. We will also include presentations on glial cell biology and genetics (channelopathies) that are relevent to an overall discussion of chronic pain.

[illegible] At the end of this session, participants will:

1) Have a better understanding of how pain management procedures work and why some are not universally effective.
2) Be cognizant of recent developments in the understanding of the etiology of neuropathic pain and how such developments are leading to new therapeutic approaches.
3) Acquire new knowledge of pain assessment and pain management protocols.
4) Improve their basic knowledge of neurobiology in a context relevant to board examination questions.

[illegible] Neurology, neurosurgery, radiology residents

08:30 [illegible] ..... *Peter Smith (Edmonton, AB)*
09:15 [illegible] ..... *Jonathan Dostrovsky (Toronto, ON)*
10:15 Discussion and break
10:45 [illegible] ..... *Matt Wheatley (Edmonton, AB)*
11:30 [illegible] ..... *Yves DeKoninck (Quebec City, QC)*
12:15 Discussion
12:45 Lunch
14:00 [illegible] ..... *Peter Light (Edmonton, AB)*
14:45 Discussion
15:15 [illegible] ..... *Ken Craig (Vancouver, BC)*
16:00 Discussion and evaluation

Victoria British Columbia

[illegible] 08:30-17:00 *(Oak Bay Room, Conference Centre)*

[illegible] David Cameron

[illegible] Interactive full day sessions featuring a comprehensive review of current topics in ALS including diagnosis and research, management and advocacy.

[illegible] At the end of this symposium, participants will be able to:

1) Describe the current clinical and pathophysiological features of ALS.
2) Identify and apply strategies to improve the function and quality of life for people with ALS.
3) Demonstrate an understanding of research initiatives and findings in ALS.

[illegible] Patients, caregivers, allied health professionals, neurologists, physiatrists and community support agencies.

08:30 Registration
09:00 Welcome ..... *David Cameron (Toronto, ON)*

[illegible] *Chairs: Hannah Briemberg (Vancouver,BC), Sanjay Kalra (Edmonton, AB)*
09:10 - [illegible] ..... *Neil Cashman (Vancouver, BC)*
09:35 - [illegible] ..... *Charles Krieger (Vancouver, BC)*
10:00 Question and answer session
10:20 Break

[illegible] *Chair: Hannah Briemberg (Vancouver, BC)*
10:40 ([illegible] ..... *TBD*
11:00 [illegible] ..... *David Cameron (Toronto, ON)*
11:20 [illegible] ..... *Dean Foti (Vancouver, BC)*
11:40 [illegible] ..... *Lorne Zinman (Toronto, ON)*
12:00 Question and answer session
12:15 Lunch break

[illegible]
13:30 ([illegible] *Moderator: TBD*
(1) [illegible] ..... *Marife Fabros, Julia Higgins*
(2) [illegible] ..... *TBD (BC Provincial Respiratory Outreach Program)*
(3) [illegible] ..... *TBD (Assistive Technologies Program [BC])*
13:30 ([illegible] *Moderator: Sanjay Kalra (Edmonton, AB)*
(1) [illegible] ..... *Hannah Briemberg (Vancouver, BC)*
(2) [illegible] ..... *John Turnbull (Hamilton, ON)*
15:00 Break

[illegible] *Chairs: David Cameron (Toronto, ON), ALSBC rep TBD*
15:15 [illegible] ..... *Andy Eisen (Vancouver, BC)*
15:45 Concluding remarks and completion of evaluation forms ..... *David Cameron (Toronto, ON), ALS BC rep TBD*

Victoria British Columbia

[illegible] 08:30-17:00 *(Crystal Ballroom, Empress)*

[illegible] Juliette Hukin, Asuri Prasad

[illegible] At the end of this session, participants will be able to:

1) Identify neurological manifestations of inborn errors of metabolism that present in childhood.
2) Differentiate between the more recent metabolic disorders that have been discovered.
3) Integrate information in analyzing and developing a clinical approach to selecting suitable laboratory investigations for inborn errors of metabolism with neurological manifestations.
4) Plan and recommend appropriate neurological management of patients presenting with suspected inborn errors of metabolism.

[illegible] Neurologists, pediatric neurologists, pediatricians, neuroscience nurses

08:30 [illegible] ..... *Mark Tarnopolsky (Hamilton, ON))*

09:15 [illegible] ..... *Miguel Cortez (Toronto, ON)*

09:55 [illegible] ..... *Asuri N. Prasad (London, ON)*

10:40 Break

10:55 [illegible] ..... *Edward Kaye (Cambridge, MA, USA)*

11:40 [illegible] ..... *Chitra Prasad (London, ON)*

12:20 [illegible] ..... *David Buckley (St. John's, NL)*

13:00 Lunch

14:30 [illegible] ..... *Sylvia Stockler (Vancouver, BC)*

15:15 [illegible] ..... *Edward Kaye, Asuri Prasad, Sylvia Stockler, Juliette Hukin*

16:15 Discussion and evaluation

Victoria British Columbia

[illegible] 18:00-20:00 *(Lecture Theatre, Conference Centre)*

[illegible] Richard McLachlan

[illegible] The diagnosis of epilepsy is based on the description of paroxysmal events. The course will demonstrate how video can be used to document spells, to distinguish epilepsy from non-epileptic conditions and to classify seizures.

[illegible] At the end of this session, participants will be able to:

1) Distinguish different seizure types using video.
2) Differentiate epilepsy from non-epileptic conditions.
3) Identify physical signs of seizure activity.

[illegible] Residents, fellows and students of neurology, adult and pediatric neurologists, neurology nurses and and EEG technologists

18:00 [illegible] ..... *Kevin Farrell (Vancouver, BC)*
18:30 [illegible] ..... *Richard Desbiens (Quebec City, QC)*
19:00 [illegible] ..... *TBD*
19:30 [illegible] ..... *Richard McLachlan (London, ON)*

[illegible] 18:00-20:00 *(Oak Bay Room, Conference Centre)*

Course generously supported through an unrestricted educational grant from UCB Pharma

[illegible] Mandar Jog

[illegible] The course is an overview of practical aspects of management in the office settings. Common yet under recognized non-motor symptoms of Parkinson's disease will be discussed. Psychiatric issues in patients with movement disorders, especially in Parkinson's, Huntington's and Tourettes will also be reviewed. In addition, a video session of unusual movement disorders rounds off the session.

[illegible] At the end of this session, participants will be able to:

1) Treat non-motor symptoms of Parkinson's disease
2) Treat the psychiatric issues facing patients with movement disorders
3) Approach a patient with dystonia, chorea and myoclonus in the office.
4) Recognize some unusual movement disorders.

[illegible] Residents, fellows, internists, geriatricians and neurologists.

18:00 [illegible] ..... *Doug Hobson (Winnipeg, MB)*
18:25 [illegible] ..... *Alex Rajput (Saskatoon, SK)*
18:50 [illegible] ..... *Kiran Rabherv (Vancouver, BC)*
19:15 [illegible] ..... *Mandar Jog (London, ON)*
19:40 Discussion and evaluation

Sanofi-aventis and Bristol-Myers Squibb are proud to be Gold sponsors of the 2008 Canadian Neurological Sciences Federation Congress

Bristol-Myers Squibb Canada is an indirect wholly owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life. Bristol-Myers Squibb Company of Canada is a leading provider of medicines to fight cancer; cardiovascular and metabolic disorders; infectious diseases, including HIV/AIDS; nervous system diseases; and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMY symbol (NYSE: BMY). Bristol-Myers Squibb Canada's operations are headquartered in Montreal, Quebec.

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY).

Sanofi-aventis is represented in Canada by the pharmaceutical company sanofi-aventis Canada Inc., based in Laval, Quebec, and by the vaccines company Sanofi Pasteur Limited, based in Toronto, Ontario. Together they employ more than 2,000 people across the country.

Bristol-Myers Squibb Canada

sanofi aventis

L'essentiel c'est la santé.

* He isn't taking this moment with his granddaughter for granted. Neither are we.
Over the past century, we have discovered some of the most important medicines and vaccines of our time. These breakthroughs have improved the treatment of asthma, cardiovascular conditions, osteoporosis, migraines and infectious diseases. As long as there is disease and suffering, we will continue to search.
Please visit our website at:
www.merckfrosst.com
MERCK FROSST
Discovering today
for a better tomorrow.

[illegible] 08:30-10:30

(Lecture Theatre, Conference Centre)

Course generously supported through an unrestricted educational grant from Sanofi Aventis / Bristol Myers Squibb

[illegible] Andrew Kirk, Richard Desbiens

[illegible] At the end of this session, participants will:

1) Understand a. the present and potential use of robotics and
   b. advances in neuroimaging in the 21st century,
2) Know the current and projected impact of neurovascular disease in the 21st century.
3) Gain understanding in the therapy of lysosomal storage disorders.

08:30 **[illegible]**

08:40 [illegible] .... *Garnette Sutherland (Calgary, AB)**

09:10 [illegible] .... *Antoine Hakim (Ottawa, ON)**

09:40 [illegible] .... *Edward Kaye (Cambridge, MA, USA)**

** denotes speaker of the Royal College of Physicians and Surgeons of Canada.*

[illegible] 10:45-12:15 *(Lecture Theatre, Conference Centre)*

[illegible]

12:30-14:00 *(Crystal Ballroom, Empress)*

This event is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) program of the Royal College of Physicians and Surgeons of Canada. It is co-developed by the Canadian Neurological Society and Boehringer-Ingelheim (Canada) Ltd. This program has been reviewed and approved for one Level 1 credit by the Canadian Neurological Society.

[illegible]

12:30-14:00 *(Saanich Room, Conference Centre)*

This event is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) program of the Royal College of Physicians and Surgeons of Canada. It is co-developed by the Canadian Neurological Society and Pfizer Canada Inc. This program has been reviewed and approved for one Level 1 credit by the Canadian Neurological Society.

[illegible]; [illegible] 14:00-17:30 *(Sidney Room, Conference Centre)*

[illegible] Michael Tymianski

[illegible] At the end of this session, participants will be able to:

1) Describe the indications for treatment of carotid stenosis and intracranial occlusive cerebrovascular disease.
2) Describe the various diagnostic modalities that exist for the treatment of carotid stenosis and intracranial occlusive cerebrovascular disease.
3) Describe the various therapeutic modalities that exist for the treatment of carotid stenosis and intracranial occlusive cerebrovascular disease.
4) Describe the timing of treatment, when indicated, for carotid stenosis and intracranial occlusive cerebrovascular disease.

[illegible] Neurologists, neurosurgeons, neuroradiologists, residents, nurses and paramedical personnel.

14:00 Introduction ..... *Michael Hill (Calgary, AB)*
14:05 [illegible] ..... *Ian Fleetwood (Halifax, NS)*
14:40 Discussion
14:55 [illegible]; [illegible] ..... *Stephen P. Lownie (London, ON)*
15:30 Discussion
15:45 [illegible] ..... *Michael Tymianski (Toronto, ON)*
16:20 Discussion
16:35 [illegible]; [illegible] ..... *Michael Hill (Calgary, AB)*
17:10 Discussion and evaluation

[illegible] 14:00-17:30 *(Lecture Theatre, Conference Centre)*

[illegible] Eric Massicotte

[illegible] To review the latest development in traumatic and non-traumatic spinal cord injury.

[illegible] As a result of this session, participants will:

1) Learn the new developments in SCI research.
2) Appreciate concepts of translational research.
3) Appreciate the different research strategies presently employed.

[illegible] All neuroscience health care professionals

14:00 [illegible] ..... *John Hurlbert (Calgary, AB)*
14:20 Discussion
14:25 &[illegible] ..... *Bradley Jacobs (Toronto, ON)*
14:45 Discussion
14:50 [illegible]; [illegible] ..... *Andrei Krassiakov (Vancouver, BC)*
15:10 Discussion
15:15 [illegible]; [illegible] ..... *Michael Fehlings (Toronto, ON)*
15:35 Discussion
15:40 [illegible]; [illegible] ..... *Rob Brownstone (Halifax, NS)*
16:00 Discussion
16:05 [illegible] ..... *Steve Casha (Calgary, AB)*
16:35 Discussion
16:40 [illegible]; [illegible]; [illegible] ..... *Eric Massicotte (Toronto, ON)*
17:00 Discussion
17:05 [illegible]; [illegible] ..... *Marcel Dvorak (Vancouver, BC)*
17:25 Discussion and evaluation

[illegible] 14:00-17:30 *(Buckingham Room, Empress)*

[illegible] Karel terBrugge

[illegible] Improvements in non-invasive imaging have led to earlier and more accurate diagnosis of intracranial vascular disorders

[illegible] At the end of this session, participants will learn:

1) Contemporary imaging of the normal intracranial venous system as well as venous occlusive disease affecting the brain in adults and children.
2) Recent advances in minimally invasive surgery and interventional techniques pertaining to brain vascular disorders.
3) To identifying different etiologies of aneurysm formation and select the most appropriate treatment modality in their management strategy.
4) To diagnose and select accurately patients with venous stroke for most appropriate treatment.

[illegible] Neurosurgeons, neuroradiologists and allied health professionals

14:00	[illegible]	*Gabrielle de Veber (Toronto, ON)*
14:20	[illegible]	*David Mikulis (Toronto, ON)*
14:40	[illegible]	*Mayank Goyal (Calgary, AB)*
15:00	[illegible]	*Karel terbrugge (Toronto, ON)*
15:20	[illegible]	*Donatella Tampieri (Montreal, QC)*
15:40	Case presentations and discussion	*Marlise de Santos (Ottawa, ON)*
16:00	Break	
16:30	[illegible]	*Ronit Agid (Toronto, ON)*
16:50	[illegible]	*Genevieve Milot (Quebec City, QC)*
17:10	Case presentations and discussion	*Marlise de Santos (Ottawa, ON)*

[illegible] 14:00-17:30 *(Oak Bay 2, Conference Centre)*

Course generously supported through an unrestricted educational grant from Boehringer Ingelheim (Canada) Inc.

[illegible] Andrew Woolfenden, Andrew Penn

[illegible] The Stroke Course is intended to update the physician on recent advances in the areas of stroke prevention and acute stroke therapy.

[illegible] At the end of this session, participants will be able to:

1) Identify recent advances in stroke care.
2) Select appropriate antiplatelet therapy for stroke prevention.
3) Understand the role of surgical management in ICH and acute ischemic stroke.
4) Understand the potential utility of advanced imaging in stroke thrombolysis.

[illegible] Neurologists, stroke neurologists, neurosurgeons, neurology residents.

14:00	[illegible]	*Greg Albers (Palo Alto, CA, USA)*
14:30	[illegible]	*Ken Butcher (Edmonton, AB)*
14:45	Discussion	
15:00	[illegible]	*Andrew Demchuk (Calgary, AB)*
15:20	Discussion	
15:30	Break	
15:45	[illegible]	*Gary Redekop (Vancouver, BC)*
16:05	Discussion	
16:15	[illegible]	*Andrew Penn (Victoria, BC)*
16:35	Discussion	
16:45	[illegible]	*Mike Sharma (Ottawa, ON)*
17:15	Discussion and evaluations	

[illegible]

Course generously supported through an unrestricted educational grant from UCB Pharma

14:00-17:30
(Oak Bay 1, Conference Centre)

[illegible] Mark Sadler, Taufik Valiante

[illegible] This half-day course is designed to provide an update on the diagnosis and management of seizures in selected populations. These target groups include patients presenting with the first seizure, management of epilepsy issues in adolescence, psychogenic non-epileptic seizures, epilepsy issues specific to women, and the surgical treatment of epilepsy in patients with low grade tumours and vascular malformations.

[illegible] At the end of this session, participants will be able to:

1) Establish an algorithm for the diagnosis and management of patients presenting with the first seizure.
2) Identify and manage epilepsy related issues unique to the adolescent population.
3) Anticipate and manage epilepsy related issues specific to women.
4) Recognize and know the therapeutic approach to patients with psychogenic non-epileptic seizures.
5) Plan a diagnostic and therapeutic approach to patients with seizures associated with low grade primary CNS tumours and vascular malformations.

[illegible] Community based neurologists (adult and pediatric), neurologists and neurosurgeons with an interest in epilepsy, and allied health professionals associated with epilepsy clinics.

14:00 [illegible] .... *Bernd Pohlmann-Eden (Halifax, NS)*
14:30 Discussion
14:40 [illegible] ..... *Peter Camfield (Halifax, NS)*
15:10 Discussion
15:20 [illegible] ..... *Danielle Andrade (Toronto, ON)*
15:50 Discussion
16:00 Break
16:15 [illegible] ..... *Elizabeth Donner, Sherese Ali (Toronto, ON)*
16:50 Discussion
17:05 [illegible] ..... *Taufik Valiante (Toronto, ON)*
17:35 Discussion and evaluation

[illegible]

14:00-17:30 *(Esquimalt Room, Conference Centre)*

[illegible] Draga Jichici, Jeanne Teitelbaum

[illegible] At the end of this session, through case histories, participants will be able to:

1) Diagnose common and less common infectious diseases affecting the nervous system.
2) Know the management of life threatening infectious diseases affecting children and adults.
3) Understand the medical and neurosurgical management of brain infections.
4) Recognize when pre-existing neurologic illness is complicated by systemic infections.
5) Identify and predict neurologic complications following solid organ transplantation.

[illegible] Practicing neurologists, neurosurgeons, residents, nurses, pediatric neurologists and neurosurgeons, ER physicians, ICU physicians.

14:00 [illegible] ..... *G. Bryan Young (London, ON)*
14:25 Discussion
14:30 [illegible] ..... *Kesh Reddy (Hamilton, ON)*
14:55 Discussion
15:00 [illegible] ..... *Charles Bolton (Kingston, ON)*
15:25 Discussion
15:30 Break
15:45 [illegible] ..... *Cecil Hahn (Toronto, ON)*
16:10 Discussion
16:15 [illegible] ..... *Jeanne Teitelbaum (Montreal, QC)*
16:40 Discussion
16:45 [illegible] ..... *Draga Jichici (Hamilton, ON)*
17:10 Discussion and evaluation

BIOVISIONARY

As a leading provider of life-saving protein therapeutics, Talecris is dedicated to achieving the next level of excellence. With a strong commitment to innovation, we continue to make advances to enrich patients' lives. Visit us at www.talecris.com.

Talecris
BIOTHERAPEUTICS

INSPIRATION. DEDICATION. INNOVATION.

Life NPH

www.lifenph.com

Hope for people with Normal Pressure Hydrocephalus

NPH Brain



Normal Brain

Neurosciences & Codman working together to solve the NPH puzzle

Typically NPH has three key symptoms: gait disturbance, cognitive impairment and urinary incontinence.

The most visible, and therefore the most recognizable sign of NPH is difficulty walking. NPH sufferers describe it as having their feet glued to the floor. Some may have trouble picking up their feet or climbing stairs or curbs, and difficulty turning, often resulting in unexpected falls.

Mild confusion can be described as a loss of interest in daily activities, forgetfulness, difficulty dealing with routine tasks and memory loss of recent events. Importantly, not everyone will have an obvious mental impairment.

The third symptom is the need to urinate often and without warning, sometimes resulting in a loss of bladder control in more severe cases. However, some NPH sufferers may never have a urinary problem.

Codman is proud to support the Canadian Neurological Sciences Federation and the Canadian Association of Neuroscience Nurses. Come visit us at Booth #1 of the 43rd Annual CNSF Congress in Victoria to explore how we can work together to solve the NPH puzzle.

Codman

Codman is a unit of Johnson & Johnson Medical Products, a Division of Johnson & Johnson, Inc.

[illegible] 08:30-10:00 *(Lecture Theatre, Conference Centre)*

[illegible] Richard Desbiens
[illegible] At the end of this session, participants will gain:

1) Knowledge in challenges for MS treatment.
2) Appreciation of personal qualities of EEG pioneers.
3) Historical roots of some basic EEG physiology and current applications.
4) Use of "old" data in focal and generalised epilepsies.
5) Identification and significance of "periodic" EEG phenomena.
6) Historical roots of ICU EEG - its current application.

08:30 Welcome and Introduction
08:40 [illegible] ..... *Peter Reickmann (Vancouver, BC)*
09:20 [illegible] ..... *Warren Blume (London, ON)*

[illegible] 08:30-10:00 *(Saanich Room, Conference Centre)*

Session generously supported through an unrestricted educational grant from Medtronic of Canada

[illegible] Derek Fewer
[illegible] At the end of this session, participants will:

1) Gain a better understanding of the natural history and treatment options for patients with AVMs.
2) Understand the incidence and the need for prevention, of brain and spinal cord injuries in Canada.

08:30 Welcome and Introduction
08:35 [illegible] ..... *J.P. Mohr (New York, NY, USA)*
09:20 [illegible] ..... *Charles Tator (Toronto, ON)*

[illegible] 10:15-12:30

General Neurosurgery 1 (pg. 37)	*Lecture Theatre, Conference Centre*
MS (pg. 4)	*Sidney Room, Conference Centre*
Stroke Neurology (pg. 41)	*Oak Bay 1, Conference Centre*
General Neurology 1 (pg. 37)	*Oak Bay 2, Conference Centre*
Neurovascular Surgery (pg. 39)	*Esquimalt Room, Conference Centre*
Trauma and Critical Care (pg. 38)	*Saanich Room, Conference Centre*
Neuro-oncology (pg. 40)	*Colwood Room, Conference Centre*

[illegible] 12:30-14:00 *(Carson Hall, Conference Centre)*

[illegible] 14:00-16:30

General Neurosurgery 2 (pg. 44)	*Lecture Theatre, Conference Centre*
General Neurology 2 (pg. 42)	*Saanich Room, Conference Centre*
Spine (pg. 43)	*Oak Bay 1, Conference Centre*
Neurovascular (pg. 47)	*Oak Bay 2, Conference Centre*
Movement Disorders, Neuromuscular, Dementia (pg. 45)	*Esquimalt Room, Conference Centre*
Epilepsy (pg. 46)	*Sidney Room, Conference Centre*
Child Neurology (pg. 45)	*Colwood Room, Conference Centre*

[illegible] 16:30-17:30 *(Carson Hall, Conference Centre)*

[illegible] 08:30-09:30 *(Lecture Theatre, Conference Centre)*

Course generously supported through an unrestricted educational grant from Neurological Sciences Foundation of Canada

08:30 Welcome and Introduction
08:40 [illegible] ..... *Dennis Choi (Atlanta, GA, USA)*

Dennis Choi

We are pleased to announce that Dennis Choi, former Executive Vice-President for Neuroscience at Merck Research Labs and current Executive Director of Emory University's Neuroscience Initiative, will be presenting as our Distinguished Guest Lecturer. Dr. Choi is currently a member of the Institute of Medicine and its Neuroscience Forum, the Executive Committee of the Dana Alliance for Brain Research, and the visiting committee advising the Harvard-MIT HST Program. Past service has included the National Academy of Science's Board on Life Sciences, multiple editorial boards (including the Board of Reviewing Editors for *Science*, and founding co-editorship of *Neurobiology of Disease*) and advisory boards, presidency of the Society for Neuroscience, chairmanship of the US National Committee to the International Brain Research Organization, and vice-presidency of the American Neurological Association.

[illegible] 09:30-09:35 *(Lecture Theatre, Conference Centre)*

[illegible] 09:35-09:45 *(Lecture Theatre, Conference Centre)*

[illegible] 09:45-10:15 *(Carson Hall, Conference Centre)*

[illegible] 10:15-12:00 *(Lecture Theatre, Conference Centre)*

Session generously supported through an unrestricted educational grant from Allergan Inc.

[illegible] Michael Hill, Dean Johnston

[illegible] ..... *TBC*
[illegible] ..... *TBC*
[illegible] ..... *TBC*

[illegible] 12:00-13:30 *(Carson Hall, Conference Centre)*

[illegible] 13:30-17:00 *(Saanich Room, Conference Centre)*

Course generously supported through an unrestricted educational grant from Merck Frosst Canada Inc.

[illegible] Marek Gawel

[illegible] New insights in migraine with aura, Trigeminal autonomic cephalalgia and interesting cases.

[illegible] At the end of this session, participants will:

1. Be familiar with new aspects of migraine with aura theory.
2. Learn the latest in Trigeminal autonomic cephalalgia.
3. Learn to indentify and understand secondary headaches.

[illegible] General neurologists

13:30 Introduction ..... *Marek Gawel (Toronto, ON)*
13:45 [illegible] ..... *Werner Becker (Calgary, AB)*
14:05 Discussion
14:15 [illegible] ..... *Marek Gawel (Toronto, ON)*
14:35 Discussion
14:45 Break
15:00 [illegible] ..... *Suzanne Christie (Ottawa, ON)*
15:20 Discussion
15:30 [illegible] ..... *Gordon Mackie (Richmond, BC)*
15:50 Discussion
16:00 [illegible] ..... *Gordon Robinson (Vancouver, BC)*
16:30 General and discussion and evaluation

[illegible] 13:30-17:00 *(Oak Bay Room, Conference Centre)*

[illegible] Christopher Honey

[illegible] This Course will provide neurosurgeons and allied workers with an update on the latest information pertaining to a variety of common neurosurgical conditions and management problems. Six speakers will provide the basic science background and relevant clinical recommendations for the following: the use of intraoperative monitoring and artificial discs and the management of malignant brain tumours, failed back syndrome, hydrocephalus, and acute stroke.

[illegible] At the end of this session, participants will be better able to:

1. Assess the utility of intraoperative monitoring,
2. Understand the potential benefits and risks of artificial discs,
3. Manage patients with malignant brain tumors,
4. Manage patients with hydrocephalus,
5. Manage patients with failed back syndrome,
6. Manage patients with acute stroke.

[illegible] General neurosurgeons

13:30 [illegible] ..... *Ryojo Akagami (Vancouver, BC)*
13:55 Discussion
14:00 [illegible] ..... *Walter Hader (Calgary, AB)*
14:25 Discussion
14:30 [illegible] ..... *Neil Duggal (London, ON)*
14:55 Discussion
15:00 [illegible] ..... *Ian Fleetwood (Halifax, NS)*
15:25 Discussion
15:30 [illegible] ..... *Brian Toyota (Vancouver, BC)*
15:55 Discussion
16:00 [illegible] ..... *Line Jacques (Montreal, QC)*
16:25 Discussion and evaluation

[illegible]

13:30-17:00 *(Esquimalt Room, Conference Centre)*

Course generously supported through an unrestricted educational grant from Roxon Medi-Tech.

[illegible] Seyed Mirsattari

[illegible] At the end of this session, participants will be better able to:

1. Learn the brain anatomy and histology as they relate to epilepsy eg. current knowledge of cotrico-cortical/cortico-subcortical connectivity.
2. Know the neuronal membrane potential, ion channels, gap junctions and excitatory/inhibitory neurotransmitters implicated in epileptogenesis.
3. Understand cellular neurophysiology and basic mechanisms of epileptogenesis.
4. Understand applied neurophysiology with a basic understanding of human EEG.

[illegible] Neurologists, neurosurgeons, pediatric neurologists and residents in neurology/neurosurgery/pediatric neurology.

13:30 [illegible] ..... *John A. Kiernan (London, ON)*
14:15 Discussion
14:20 [illegible] ..... *Michael Poulter (London, ON)*
14:55 Discussion
15:10 [illegible] .. *Brian R. Christie (Victoria, BC)*
15:55 Discussion
16:00 [illegible] ..... *Michael Poulter (London, ON)*
16:45 Discussion and evaluation

[illegible]

13:30-17:00 *(Colwood Room, Conference Centre)*

[illegible] Claude Martin

[illegible] To provide a forum to discuss medico-legal issues with Canadian neurologists, neurosurgeons, neuroradiologists and lawyers involved in this area.

[illegible] At the end of this symposium participants will be able to:

1) Identify two preventative practice behaviours to minimize the risk of medico-legal difficulties.
2) Develop two strategies to prevent and, if necessary, to respond to adverse events in neurological and neurosurgical cases.
3) Assess the medico-legal implications of clinical situations related to neurological and neurosurgical cases.

[illegible] practicing neurologists, neurosurgeons and neuroradiologists in Canada.

13:30 [illegible] ..... *William Tucker (Toronto, ON), Claude Martin, jr. (Ottawa, ON), Barbara J. Norell (Vancouver, BC)*
13:50 Discussion
14:00 [illegible] ..... *William Tucker, Claude Martin, jr., Barbara J. Norell*
14:20 Discussion
14:30 [illegible] ..... *William Tucker, Claude Martin, jr., Barbara J. Norell*
14:50 Discussion
15:00 [illegible] ..... *William Tucker, Claude Martin, jr., Barbara J. Norell*
15:30 Break
15:45 [illegible] ..... *William Tucker, Claude Martin, jr., Barbara J. Norell*
16:05 Discussion
16:15 Panel Symposium Topics: the following topics will be discussed as time permits:

- Handling an unexpected outcome
- How to prepare for discovery
- Development of clinical practice guidelines
  - o when does a new guideline become a "gold standard?"
  - o medico-legal implications of policies and guidelines

16:45 Discussion and evaluation

[illegible] 13:30-17:00

(Sidney Room, Conference Centre)

Course generously supported through an unrestricted educational grant from Pfizer Canada Inc.

[illegible] Howard Feldman

[illegible] This course will offer an update on a range of dementias and cognitive disorders that face the practicing neurologist, neurosurgeon, and allied neurological health professional. The spectrum of dementias that will be covered will include the very common to the rare. The focus of the course will include the application of guidelines to practice and the integration of recent research advances to clinical care. The recent Canadian Guidelines for the Diagnosis and Treatment of Dementia will be covered as well as advances in frontotemporal dementia, prion diseases, and the potential for immunotherapy to emerge as an important treatment direction in neurodegenerative diseases.

[illegible] At the end of this session, participants will:

1. Be familiar with and able to apply the Canadian Consensus Guidelines on the Diagnosis and Treatment of Dementia in their clinical practice,
2. Understand the direction of current therapeutic research in neurodegenerative dementias.
3. Be updated on the spectrum of dementias including the uncommon but treatable causes.

[illegible] Practicing general neurologists, neurosurgeons, residents, neuroscience graduate students, neurological nurses and neuropsychologists involved in cognitive assessments.

13:30 Welcome and course introduction ..... *Howard Feldman (Vancouver, BC)*
13:45 [illegible] ..... *Howard Chertkow (Montreal, QC)*
14:05 Discussion
14:15 [illegible] ..... *Tiffany Chow (Toronto, ON)*
14:35 Discussion
14:45 [illegible] ..... *Howard Feldman (Vancouver, BC)*
15:05 Discussion
15:15 Break
15:30 ([illegible] ..... *Gerard Jansen (Ottawa, ON)*
15:50 Discussion
16:00 [illegible] ..... *Neil Cashman (Vancouver, BC)*
16:20 Discussion
16:30 [illegible] ..... *John Ringman (Los Angeles, CA, USA)*
16:50 Discussion and evaluation

Victoria British Columbia

[illegible] 13:30-17:00 *(Lecture Theatre, Conference Centre)*

[illegible] Ashfaq Shuaib

[illegible] Recent advances and current updates in management of common neurological disorders.

[illegible] At the end of this session, participants will:

1. Have a clear idea of recent advances in management of myasthenia gravis.
2. Be able to best manage patients with TIAs.
3. Be able to identify recent advances in evaluation and management of epilepsy.
4. Recognize and know the therapeutic approach to patients with psychogenic non-epileptic seizures.
5. Be able to summarize recent advances in management of multiple sclerosis

[illegible] Neurologists, neurosurgeons, residents and nurses.

13:30	**[illegible]**	*G. Bryan Young (London, ON)*
14:00	Discussion	
14:10	**[illegible]**	*Gregg Blevins (Edmonton, AB)*
14:40	Discussion	
14:50	Break	
15:05	**[illegible]**	*Zaeem Siddiqi (Edmonton, AB)*
15:35	Discussion	
15:45	**[illegible]**	*Ashfaq Shuaib (Edmonton, AB)*
16:10	Discussion	
16:20	**[illegible]**	*TBA*
16:50	Discussion and evaluation	

&[illegible] 13:30-17:00 *(Crystal Ballroom, Empress)*

Course generously supported through an unrestricted educational grant from Talecris Biotherapeutics

[illegible] Mike Nicolle

[illegible] The Neuromuscular Course consists of a series of talks on common neuromuscular topics relevant to everyday practice, with ample time for audience discussion. Talks are given by Canadian Neuromuscular 'experts'. The course is aimed at neurology and physiatry residents, community and academic neurologists and physiatrists. Topics are chosen based on the needs of potential audience members, as obtained by an email/fax survey. Material presented will include clinical and basic science as it pertains to the pathophysiology of the disease entities discussed.

[illegible] At the end of this session participants will be able to:

1) Gain an understanding of the common disorders affecting the PNS in the setting of HIV infection.
2) Confidently diagnose, using clinical skills and appropriate diagnostic testing, small fibre neuropathies in order to be able to establish an appropriate therapeutic strategy for their treatment.
3) Plan a diagnostic strategy for patients with peripheral neuropathy based on clinical and electrodiagnostic features.
4) Integrate knowledge of recent advances in the field of neuromuscular diseases into the practical management of patients with these diseases.

[illegible] Allied health care workers, neurology and physiatry residents and fellows; academic and community neurologists and physiatrists with an interest or learning need in the field of neuromuscular neurology and physiatry.

13:30 [illegible] ..... *Alister Prout (Vancouver, BC)*
14:05 Discussion
14:15 [illegible] ..... *John Stewart (North Vancouver, BC)*
14:50 Discussion
15:00 Break
15:30 [illegible] ..... *Ian Grant (Halifax, NS)*
16:10 Discussion
16:15 [illegible] ..... *Shannon L. Venance (London, ON)*
16:50 Discussion and evaluation

2007 – 2008 Board of Directors and Committee Chairs

Andrew Kirk
- *CNSF President*
- *NSFC President*
- *CNS Past President*

Garth Bray
- *CNSF Vice-President*
- *NSFC Vice-President*
- *CNS Member*



George Elleker
- *CNSF Vice-President*
- *NSFC Vice-President*
- *CSCN Past President*

Jerome Yager
- *CNSF Board Member*
- *NSFC Board Member*
- *CACN President*

Mary Connolly
- *CNSF Board Member*
- *NSFC Board Member*
- *CACN Vice-President*

Derek Fewer
- *CNSF Board Member*
- *NSFC Board Member*
- *CNSS President*

J. Max Findlay
- *CNSF Board Member*
- *NSFC Board Member*
- *CNSS Vice-President*

Richard Desbiens
- *CNSF Board Member*
- *NSFC Board Member*
- *CNS President*

Lyle Weston
- *CNSF Board Member*
- *NSFC Board Member*
- *CNS Vice- President*

Manouchehr Javidan
- *CNSF Board Member*
- *NSFC Board Member*
- *CSCN President*

Ming Chan
- *CNSF Board Member*
- *NSFC Board Member*
- *CSCN Vice-President*

Artur Szymczak
- *CNSF Board Member*
- *NSFC Board Member*
- *Residents' Rep. CNSS*

Teneille Gofton
- *Residents' Rep. CNS*

unavailable

Michael Esser
- *Residents' Rep. CACN*

Mark Hamilton
- *CNSF/NSFC Past President - Non-voting*

Dan Morin
- *CEO*

Non-voting

G. Bryan Young
- *Journal Editor-in-chief*
- *CNS & CSCN Member*

Mike Tymianski
- *CNSF Scientific Program Committee Chair*
- *CNSS Member*

Brian Wheelock
- *CNSF Professional Development Committee Chair*
- *CNSS Member*



Charles Tator
- *CBANHC Chair*

Legend:
CNSF - *Canadian Neurological Sciences Federation;* NSFC - *Neurological Sciences Foundation of Canada;* CNS - *Canadian Neurological Society;* CNSS - *Canadian Neurosurgical Society;* CSCN - *Canadian Society of Clinical Neurophysiologists;* CACN - *Canadian Association of Child Neurology;* CBANHC - *Canadian Brain and Nerve Health Coalition*



UPPER LEVEL

EXHIBITOR LIST	BOOTH NUMBER
Allergan	26
Bayer Healthcare	55
Biogen Idec	16
Boehringer / Lilly	40
Boehringer Ingelheim	31
Canada Microsurgical	37
Carl Zeiss	43
Elsevier	39
Galen	25
Genzyme	22
Grass Technologies	44
Interior Health	42
Johnson & Johnson	1
Karl Storz	53
King Medical	18
Leica Microsystems	15
Alpine Biomed	47
Lundbeck	5
Medtronic	9
Merck Frosst	36
Neurologica	54
Pfizer Canada	3
Prestwick Pharmaceuticals	20
Roxon Medi-Tech	35
Sanofi Aventis / BMS	6
Stellate	33
Stryker	12
Summit	21
Talecris	34
Teva Neurosciences	13
Trudell Medical Marketing	17
UCB Pharma	14
XLTEK	11

[illegible]

[illegible]

V Ramaswamy (Edmonton), J Horton (Edmonton), B Vandermeer (Edmonton), N Buscemi (Edmonton), SP Miller (Vancouver), JY Yager (Edmonton)*

[illegible]

[illegible]

S Di Maio (Vancouver), R Akagami (Vancouver)*

[illegible]

[illegible]

BY Kim (Toronto), W Jiang (Toronto), WC Chan (Toronto), JT Rutka (Toronto)*

Victoria British Columbia

[illegible]’[illegible] ([illegible]&[illegible] ([illegible]&[illegible]&[illegible]

[illegible]%[illegible] [illegible]%[illegible]&[illegible]K[illegible]%[illegible] [illegible]

JUNE 18, 2008

LECTURE THEATRE, CONFERENCE CENTRE

[illegible] [illegible] . [illegible]

A Henri-Bhargava (Montréal), AC Simioni (Montréal), LK Fellows (Montréal)*

[illegible] [illegible] [illegible]

J Beiko (Winnipeg), A Kaufmann (Winnipeg)*

[illegible] [illegible] [illegible] (

Max Findlay (Edmonton), R Macdonald (Toronto), N Kassell (Charlottesville), S Mayer (New York), D Ruefenacht (Geneva), P Schmiedek (Mannheim), S Weidauer (Frankfurt), A Pasqualin (Verona)*

[illegible] [illegible] ([illegible]

S Di Maio (Vancouver), R Akagami (Vancouver)*

[illegible] [illegible] [illegible]

*WJ Hader (Saskatoon)**

[illegible] [illegible] [illegible]

MG Fehlings (Toronto), A Vaccaro (Philadelaphia), B Aarabi (Baltimore), M Dvorak (Vancouver), C Shaffrey (Charlottesville), E Massicotte (Toronto), C Fisher (Vancouver), R Rampersaud (Toronto), S Lewis (Toronto)*

[illegible]&[illegible] &[illegible] [illegible]

[illegible]&[illegible]W[illegible]

JUNE 19, 2008

OAK BAY 2, CONFERENCE CENTRE

[illegible] [illegible] [illegible]

*PM Macleod (Victoria)**

[illegible] [illegible] [illegible]

JJ Shankar (Ottawa), S Chakraborty (Ottawa), T Nguyen (Ottawa), MD Santos (Ottawa), C Lum (Ottawa)*

[illegible] [illegible] [illegible]

G Pfeffer (Vancouver), S Sirrs (Vancouver), HD Vallance (Vancouver), NK Wade (Vancouver), PJ Waters (Vancouver), VA Wong (Vancouver), MM Mezei (Vancouver)*

[illegible] [illegible] [illegible]

TM Al-Harbi (Hamilton), L Bainbridge (Hamilton), MJ McQueen (Hamilton), M Tornopolsky (Hamilton)*

[illegible] [illegible] ([illegible]

M Chitre (Chitre), A Parker (Cambridge), G Woods (Cambridge)*

[illegible]

[illegible] [illegible] [illegible]
D Blacquiere (Ottawa), G Gubitz (Halifax), D Dupere (Halifax), D MacLeod (Halifax), S Phillips (Halifax)*

[illegible] [illegible] [illegible]
*C Jobin (Montréal), N Blais (Montréal), P Bourgouin (Montréal), F Moreau (Montréal), S Lanthier (Montréal)**

[illegible] [illegible] [illegible]
BY Kim (Toronto), W Jiang (Toronto), WC Chan (Toronto), JT Rutka (Toronto)*

[illegible]

[illegible]

JUNE 19, 2008
LECTURE THEATRE, CONFERENCE CENTRE

[illegible] [illegible] [illegible]
JM Drake (Toronto), J Riva-Cambrin (Salt Lake City), A Jea (Houston), K Aguste (Toronto), M Lamberti-Pasculli (Toronto)*

[illegible] [illegible] [illegible]
K Schultheiss (New York), YG Jang (Chicago), RN Yanowitch (Chicago), J Tolentino (Chicago), DJ Curry (Chicago), J Luders (Cleveland), F Asgarzadie-Gadim (Chicago), R Macdonald (Toronto)*

[illegible] [illegible] [illegible]
*M Hamilton (Calgary)**

[illegible] [illegible] [illegible]
JD Pearl (Montréal), DJ Sirhan (Montréal), D Tampieri (Montréal)*

[illegible] [illegible] [illegible]
CJ O'Kelly (Toronto), MC Wallace (Toronto)*

[illegible] [illegible] [illegible]
AM Parr (Toronto), I Kulbatski (Toronto), T Zahir (Toronto), X Wang (Toronto), C Yue (Toronto), A Keating (Toronto), CH Tator (Toronto)*

[illegible] [illegible] [illegible]
JJ Kelly (Calgary), GR Sutherland (Calgary), JK Saunders (Winnipeg), I Latour (Calgary)*

[illegible] [illegible] [illegible]
JA King (Toronto), JT Rutka (Toronto)*

[illegible] [illegible] [illegible]
M Vassilyadi (Ottawa), Z Tataryn (Manhattan), K Udjus (Ottawa)*

[illegible]- %[illegible]&[illegible] [illegible]

[illegible]

JUNE 19, 2008

SAANICH ROOM, CONFERENCE CENTRE

[illegible] ([illegible]
JC Furlan (Toronto), D Kattail (Toronto), MG Fehlings (Toronto)*

[illegible] [illegible]
JC Furlan (Toronto), D Kattail (Toronto), ND Ferguson (Toronto), MG Fehlings (Toronto)*

[illegible] ([illegible]
SA El-Zuway (Hamilton), D Jichici (Hamilton), BW Lo (Hamilton), F Farrokhyar (Hamilton), R Petrovic (Hamilton), R Elzuway (Hamilton)*

[illegible] [illegible]
K Ng (Toronto), R Green (Toronto), B Colella (Toronto), D Lazinski (Toronto), R Agid (Toronto), G Greenberg (Toronto), D Mikulis (Toronto)*

[illegible] [illegible]
JS Teitelbaum (Montréal), T Slaoui (Paris), D Fish (Montréal)*

[illegible] [illegible]
A Singhal (Vancouver), K Pakzad-Vaezi (Vancouver)**

[illegible] [illegible]
JC Furlan (Toronto), MB Bracken (New Haven), MG Fehlings (Toronto)*

[illegible] [illegible]
*R Sahjpaul (North Vancouver)**

[illegible] [illegible]
D Louw (Edmonton), P Green (Edmonton)*

&[illegible]- [illegible]. [illegible]- [illegible] [illegible] [illegible]

[illegible]

JUNE 19, 2008

ESQUIMALT ROOM, CONFERENCE CENTRE

[illegible] [illegible]
*IG Fleetwood (Halifax)**

[illegible] [illegible]
SS Belkhair (Halifax), IG Fleetwood (Halifax)*

[illegible] [illegible]
EE Dyer (London), S Lownie (London)*

[illegible] [illegible]
GJ Redekop (Vancouver), CS Haw (Vancouver), M Heran (Vancouver)*

[illegible] [illegible]

[illegible]

JH Wong (Calgary), S Sanyal (Calgary), WF Morrish (Calgary), ME Hudon (Calgary), JA Silvaggio (Calgary), WY Hu (Calgary), G Mayank (Calgary), MD Hill (Calgary)*

[illegible] [illegible]

[illegible]

GJ Redekop (Vancouver), CS Haw (Vancouver), M Heran (Vancouver)*

[illegible] [illegible]

[illegible]

L Thines (Toronto), R Agid (Toronto), AR Dehdashti (Toronto), L Da Costa (Toronto), C Wallace (Toronto), KG Ter Brugge (Toronto), M Tymianski (Toronto)*

[illegible] [illegible]

[illegible]

MP Dos Santos (Ottawa), R Agid (Toronto), R Willinsky (Toronto), KG terBrugge (Toronto), W Montanera (Toronto), TR Marotta (Toronto)*

[illegible] [illegible]

[illegible]

CS Sutherland (Calgary), MD Hill (Calgary), AM Kaufmann (Winnipeg), JA Silvaggio (Winnipeg), AM Demchuk (Calgary), GR Sutherland (Calgary)*

[illegible]

[illegible]

JUNE 19, 2008

COLWOOD ROOM, CONFERENCE CENTRE

[illegible] [illegible]

[illegible]

R Madhok (Pittsburgh), AB Kassam (Pittsburgh), C Snyderman (Pittsburgh), P Gardner (Pittsburgh), R Carrau (Pittsburgh), D Prevedello (Pittsburgh)*

[illegible] [illegible]

[illegible]

IH Alahmed (Toronto), S Vachhrajani (Toronto), K Auguste (Toronto), M Shroff (Toronto), P Dirks (Toronto), J Drake (Toronto), J Rutka (Toronto)*

[illegible] [illegible]

[illegible]

D Yamashita (Kingston), T Ailon (Vancouver), M Sargent (Vancouver), A Singhal (Vancouver), K Goddard (Vancouver), C Fryer (Vancouver), J Hukin (Vancouver)*

[illegible] [illegible]

[illegible]

SA Almubarak (Vancouver), Y Gan (Vancouver), P Steinbok (Vancouver), G Hendson (Vancouver), K Poskitt (Vancouver), H Nadel (Vancouver), K Goddard (Vancouver), J Hukin (Vancouver)*

[illegible] [illegible]

[illegible]

*S Gul (North Vancouver)**

[illegible] [illegible]

[illegible]

J Hukin (Vancouver), T Yamashita (Vancouver), S Yip (Charlestown), T Ailon (Vancouver), M Sargent (Vancouver), A Singhal (Vancouver), G Hendson (Vancouver), J Maguire (Vancouver), C Hawkins (Toronto), SE Dunn (Vancouver)*

[illegible] [illegible]

[illegible]

S Kirby (Halifax), R Brownstone (Halifax), RJ Macaulay (Halifax)*

[illegible] [illegible] [illegible]
JJ Chong (London), RH Hammond (London), DH Lee (London), DR Macdonald (London), JF Megyesi (London), SM Mirsattari (London)*

%- [illegible] [illegible]

[illegible]

JUNE 19, 2008

SIDNEY ROOM, CONFERENCE CENTRE

[illegible] [illegible] [illegible]
B Banwell (Toronto), J Kennedy (Toronto), A Bar-Or (Montréal), D Sadovnick (Vancouver), D Arnold (Montréal)*

[illegible] [illegible] %[illegible]&[illegible]
S Venkateswaran (Montréal), M Sacchetti (Boston), D Arnold (Montréal), D Sadovnick (Vancouver), J Kennedy (Toronto), D Gagne (Montréal), B Banwell (Toronto), A Bar-Or (Montréal), DK Simon (Boston)*

[illegible] [illegible] [illegible]
A Sayao (Vancouver), G Ebers (Oxford)*

[illegible] [illegible] [illegible]
*A Bethune (Toronto), D Mabbott (Toronto), C Rockel (Toronto), J Sled (Toronto), B Banwell (Toronto)**

[illegible] [illegible] [illegible]
PS Giacomini (Montréal), IR Levesque (Montréal), S Narayanan (Montréal), L Ribeiro (Montréal), GB Pike (Montréal), DL Arnold (Montréal)*

[illegible] [illegible] [illegible]
E Ursell (Toronto), B Helen (Toronto), D Callen (Toronto), S Manohar (Toronto), B Banwell (Toronto)*

[illegible] [illegible] %[illegible]
AD Tu (Vancouver), A Traboulsee (Vancouver)*

[illegible] [illegible] [illegible]
KS Waspe (Langley), A Krassioukov (Vancouver), G Vorobeychik (Burnaby)*

[illegible] [illegible] [illegible]
*SD Brass (Boston)**

[illegible]K[illegible]

[illegible] %[illegible] [illegible]

JUNE 19, 2008

OAK BAY 1, CONFERENCE CENTRE

[illegible] [illegible] [illegible]
AY Poppe (Calgary), SR Majumdar (Edmonton), T Jeerakathil (Edmonton), W Ghali (Calgary), AM Buchan (Oxford), MD Hill (Calgary)*

Victoria British Columbia

[illegible]

[illegible]
AY Yu (Montréal)*, MR Keezer (Montréal), B Zhu (Montréal), C Wolfson (Montréal), R Côté (Montréal)

[illegible]
JS Teitelbaum (Montréal)*, R von Kummer (Dresden), Gregory (Stanford)

[illegible]
AY Poppe (Calgary)*, AM Buchan (Oxford), MD Hill (Calgary)

[illegible]
Y Nadeau (Québec)*, G Milot (Québec), J Gariepy (Québec)

[illegible]
M Eesa (Calgary)*, MD Hill (Calgary), M Goyal (Calgary)

[illegible]
N Asdaghi (Edmonton)*, A Shauib (Edmonton), M Muratoglu (Edmonton), T Jeerakathil (Edmonton)

[illegible]
D Jichici (Hamilton), BW Lo (Hamilton)*, A Serb (Hamilton), R Petrovic (Hamilton)

[illegible]
BW Lo (Hamilton)*, N Murty (Hamilton), D Jichici (Hamilton), P Gregor (Hamilton), N Zagzoog (Hamilton)

[illegible]

June 19, 2008
Saanich Room, Conference Centre

[illegible]
BF Menezes (Liverpool)*, G Francis (Wirral), T Solomon (Liverpool)

[illegible]
NG Hatfield (Vancouver)*

[illegible]
TE Gofton (London)*, GB Young (London), PA Chouinard (London), A Dencev (London), F Bihari (London), M Nicolle (London), DH Lee (London), MD Sharpe (London), SM Mirsattari (London)

[illegible]
KS Waspe (Langley)*, G Vorobeychik (Burnaby)

[illegible]
M Chitre (Cambridge)*, S Bhakthavalsala (Cambridge), PN Hall (Cambridge), S Burton (Cambridge), T Ahmad (Cambridge), W Kelsall (Cambridge)

[illegible] [illegible]
E Riou (Montréal), S Ghosh (Montréal), E Francoeur (Montréal), M Shevell (Montréal)*

[illegible] [illegible]
JA McCombe (Edmonton), RN Auer (Calgary), S Houston (Edmonton), MJ Gill (Calgary), C Power (Edmonton)*

[illegible] [illegible]
*M Dakermandji (Montréal),S Lanthier (Montréal)**

[illegible] [illegible]
A Kirton (Calgary), R Chen (Toronto), S Friefeld (Toronto), C Gunraj (Toronto), A Pontigon (Toronto), G deVeber (Toronto)*

[illegible] [illegible]
F Moore (Montréal), C Chalk (Montréal)*

[illegible] &

[illegible] %

JUNE 19, 2008

OAK BAY 1, CONFERENCE CENTRE

[illegible] [illegible]
JC Furlan (Toronto), B Aarabi (Baltimore), MG Fehlings (Toronto)*

[illegible] [illegible]
MG Fehlings (Toronto), B Kopjar (Seattle), E Massicotte (Toronto), T Yoon (Atlanta), P Arnold (Kansas City), D Brodke (Salt Lake City), W Eric (Boston), C Shaffrey (Charlottesville), A Vaccaro (Philadelphia), M Janssen (Denver)*

[illegible] [illegible]
MF Shamji (Ottawa), C Brown (Durham), C Cook (Durham), RE Isaacs (Durham)*

[illegible] [illegible]
*K Kumar (Regina)**

[illegible] [illegible]
FC Lam (Edmonton), BJ Irwin (Vancouver), KJ Poskitt (Vancouver), P Steinbok (Vancouver)*

[illegible] [illegible]
TE Darsaut (Edmonton),MM Sartawi (Edmonton), P Dhaliwal (Edmonton), RJ Fox (Edmonton)*

[illegible] [illegible]
S Berry (Halifax), R Murphy (Halifax), SD Christie (Halifax)

[illegible] [illegible]
S Gul (North Vancouver), R Sahjpaul (North Vancouver)*

Victoria British Columbia

[illegible] [illegible]
N Deis (Edmonton), M Findlay (Edmonton)*

[illegible] [illegible]
DH Zhang (Hamilton), K Reddy (Hamilton)*

[illegible]

[illegible]

JUNE 19, 2008
LECTURE THEATRE, CONFERENCE CENTRE

K-[illegible] [illegible]
MG Hamilton (Calgary), F Girgis (Calgary), T Myles (Calgary), W Hader (Calgary)*

K-[illegible] [illegible]
*K Reddy (Hamilton), R Hollenberg (Hamilton), K Kamian (Hamilton)**

K-[illegible] [illegible]
N McLaughlin (Montréal), M Lévêque (Montréal), D Laudy (Montréal), MW Bojanowski (Montréal)*

K-[illegible] [illegible]
S Brien (Ottawa), D Louw (Edmonton)*

K-[illegible] [illegible]
*GR Sutherland (Calgary)**

K-[illegible] [illegible]
M Kis (Halifax), I Mendez (Halifax)*

K-[illegible] [illegible]
CA Serrano-Almeida (Calgary), J Larsson (Calgary), YP Starreveld (Calgary), GR Sutherland (Calgary)*

K-[illegible] [illegible]
S Vachhrajani (Toronto), CS Fawaz (Sherbrooke), D Mathieu (Sherbrooke), C Menard (Toronto), R Taylor (Toronto), M Bernstein (Toronto)*

K-[illegible] [illegible]
T Ailon (Vancouver), A Singhal (Vancouver), S Michael (Vancouver), T Yamashita (Kingston), C Fryer (Vancouver), K Goddard (Vancouver), J Hukin (Vancouver)*

K-[illegible] [illegible]
J Green (St. John's),FB Maroun (St. John's), L Best (St. John's), AH Kwan (St. John's)*

[illegible] &[illegible]- [illegible]

[illegible]

JUNE 19, 2008

COLWOOD ROOM, CONFERENCE CENTRE

[illegible] [illegible] [illegible]
HC Glass (San Francisco), TN Pham (San Francisco), B Danielsen (Davis), D Towner (Davis), D Glidden (San Francisco), Y Wu (San Francisco)*

[illegible] [illegible] [illegible]
M Vassilyadi (Ottawa), Z Tataryn (Manhattan), S Dagenais (Ottawa), M Blayney (Ottawa), E Ventureyra (Ottawa)*

[illegible] [illegible] ([illegible]
JY Yager (Edmonton), E Armstrong (Edmonton)*

[illegible] [illegible] [illegible]
V Ramaswamy (Edmonton), J Horton (Edmonton), B Vandermeer (Edmonton), N Buscemi (Edmonton), SP Miller (Vancouver), JY Yager (Edmonton)*

[illegible] [illegible] [illegible]
J Srinivasan (Vancouver), S Miller (Vancouver), TG Phan (Melbourne), MT Mackay (Melbourne)*

[illegible] [illegible] %[illegible]
J Vaz (Calgary), WJ Hader (Calgary), M Hamilton (Calgary), D Slick (Calgary)*

[illegible] [illegible] [illegible]
DT Warren (Vancouver), T Bowen-Roberts (Vancouver), R Purdy (Vancouver), P Steinbok (Vancouver)*

[illegible] [illegible] ([illegible]
R Hung (Toronto), M Rafay (Winnipeg), T Sutcliffe (Palo Alto), J Smallhorn (Toronto), L Benson (Toronto), D MacGregor (Toronto)*

[illegible] [illegible] [illegible]
L Hamiwka (Calgary), B Anderson (Calgary)*, X Wei (Calgary), W Abou Reslan (Calgary), M Sheriff (Calgary), E Wirrell (Rochester)*

[illegible] [illegible] [illegible]
KM Barlow (Calgary), D Dewey (Calgary)*

%[illegible]. [illegible]%[illegible]&[illegible] [illegible]/&[illegible]- [illegible]%- [illegible]- [illegible]/[illegible]%[illegible]&[illegible]

[illegible]([illegible] [illegible]- [illegible]&[illegible] [illegible]&

JUNE 19, 2008

ESQUIMALT ROOM, CONFERENCE CENTRE

%-[illegible] [illegible] [illegible]
*A Shankar (Calgary), N de Bruin (Lethbridge), S Bonfield (Calgary), L Derwent (Calgary), M Eliasziw (Calgary), L Brown (Lethbridge), O Suchowersky (Calgary)**

%-[illegible] [illegible] [illegible]
A Dionne (London), MW Nicolle (London), AF Hahn (London)*

Victoria British Columbia

[illegible]

[illegible]
V Bril (Toronto), P Donofrio (Nashville), C Deng (Research Triangle Park), K Hanna (Research Triangle Park), RA Hughes (London), H Katzberg (Palo Alto), PA van Doorn (Rotterdam)*

[illegible]
C Chalk (Montréal), E Hattan (Montréal), R Postuma (Montréal)*

[illegible]
*SK Baker (Hamilton)**

[illegible]
JK Mah (Calgary), CA Stoian (Calgary), N Liu (Calgary), E Goia (Calgary)*

[illegible]
A Kirk (Saskatoon), M Crossley (Saskatoon), S Harder (Saskatoon), J Basran (Saskatoon), V Dal Bello-Haas (Saskatoon), D Morgan (Saskatoon), N Stewart (Saskatoon), J Biem (Ottawa), D Forbest (Edmonton), L Holfeld (Saskatoon)*

[illegible]
OA Ayoub (Vancouver), J Money (Vancouver), H Feldman (Vancouver), G Hsiung (Vancouver)**

[illegible]
HM Chertkow (Montréal), N Philips (Montréal), H Bergman (Montréal), V Whitehead (Montréal), C Wolfson (Montréal)*

[illegible]

[illegible]

June 19, 2008
Sidney Room, Conference Centre

[illegible]
P Dhaliwal (Calgary), T Myles (Calgary), Y Starreveld (Calgary), N Pillay (Calgary), S Wiebe (Calgary), W Hader (Calgary)*

[illegible]
L Hamiwka (Calgary), E Sherman (Calgary), E Wirrell (Rochester), C Yu (Calgary)*

[illegible]
OV Finlayson (Waterloo), SM Mirsattari (London), PA Derry (London), JG Burneo (London), DC Diosy (London), RS McLachlan (London), BG Young (London), WT Blume (London)*

[illegible]
SW Wong (Los Angeles), SM Mirsattari (London), F Bihari (London), D Bandur (London), DH Lee (London)*

[illegible]
SK Balagopal (London), J Chong (London), SM Mirsattari (London)*

[illegible]
SM Mirsattari (London), A Patel (London), WT Blume (London)*

&-[illegible] [illegible]
EJ Donner (Toronto), F Wang (Toronto), M Malone (Toronto), D Kadis (Toronto), EW Pang (Toronto)*

&-[illegible] [illegible]
HB Sarnat (Calgary), L Flores-Sarnat (Calgary)*

&-[illegible] [illegible]
M del Campo (Toronto), P Abdemalik (Toronto), C Wu (Toronto), L Zhang (Toronto), P Carlen (Toronto)*

&-[illegible] [illegible]
JT Rutka (Toronto), A Kwan (Toronto), JM Drake (Toronto), C Snead (Toronto), S Weiss (Toronto)*

&[illegible]- [illegible]. [illegible]- [illegible]

[illegible]

JUNE 19, 2008
OAK BAY 2, CONFERENCE CENTRE

[illegible]-[illegible] [illegible]
JJ Kelly (Calgary), GR Sutherland (Calgary)*

[illegible]-[illegible] [illegible]
LB da Costa (Toronto), MQ Ribeiro (Porto), PR Howard (Toronto), L Thines (Toronto), A Dehdashti (Toronto), KG ter Brugge (Toronto), RA Willinsky (Toronto)*

[illegible]-[illegible] [illegible]
D Tampieri (Montréal), M Cortes (Montréal), D Sirhan (Montréal), D Sinclair (Montréal)*

[illegible]-[illegible] [illegible]
FB Maroun (St. John's), B Fernandez (St. John's), B Noble (St. John's), JC Jacob (St. John's), GP Murray (St. John's)*

[illegible]-[illegible] [illegible]
LB da Costa (Toronto), J Spears (Toronto), I Penn (Vancouver), DR Ricci (Vancouver), I McDougall (Vancouver), A Marko (Vancouver), G Bourne (Vancouver), B Qiang (Toronto), TR Marotta (Toronto)*

[illegible]-[illegible] [illegible]
R Agid (Toronto), S Lee (Toronto), RA Willinsky (Toronto), RI Farb (Toronto), KG Terbrugge (Toronto)*

[illegible]-[illegible] [illegible]
RT Grondin (Boston), ER Smith (Boston), R Scott (Boston)*

[illegible]-[illegible] [illegible]
*JH Wong (Calgary)**

[illegible]-[illegible] [illegible]
M Audet (Montréal), J Raymond (Montréal), D Roy (Montréal), F Guilbert (Montréal), JB Chew (Montréal), A Weill (Montréal)*

[illegible]-[illegible] [illegible]
A Dehdashti (Toronto), L Thines (Toronto), L Da costa (Toronto), M Schwartz (Toronto), K TerBrugge (Toronto), R Willinski (Toronto), M Tymianski (Toronto), C Wallace (Toronto)*

[illegible]

([illegible]
*N Al-Macki (Montréal), S Miller (Vancouver), N Hall (Montréal), M Shevell (Montréal)**

([illegible] ***E. coli*** [illegible]
R RamachandranNair (Hamilton), G LeBlanc (Hamilton), R Mesterman (Hamilton)*

([illegible]
RJ Huntsman (Saskatoon), EG Lemire (Saskatoon), CP Dunham (Vancouver)*

([illegible]
M Labib (London), A Ranger (London)*

([illegible]
AM Ranger (London), M Salvadori (London), G Morrison (London), L Jardine (London), L Perlman (London), A. Szymczak (London)*

[illegible]

([illegible]
WM McEachern (Regina), A Kirk (Saskatoon), D Morgan (Saskatoon), M Crossley (Saskatoon), C Henry (Saskatoon)*

([illegible]
E Landry St-Pierre (Montréal), P Rosa (Montréal), G Massarweh (Montréal), A Alliaga (Montréal), S Mzengeza (Montréal), M Bédard (Montréal), J Soucy (Montréal)*

([illegible]
E Landry St-Pierre (Montréal), P Rosa (Montréal), G Massarweh (Montréal), S Mzengeza (Montréal), M Bédard (Montréal), J Soucy (Montréal)*

([illegible]
S Mann (Vancovuer), MB Coulthart (Winnipeg), JT Kelsall (Vancouver), P Gambetti (Cleveland), GH Jansen (Ottawa), S Spacey (Vancouver)*

[illegible]

([illegible]
JF Tellez-Zenteno (Saskatoon), A Kirk (Saskatoon), J McEachern (Saskatoon), W VanBuren (Saskatoon), L Hernández-Ronquillo (Saskatoon)*

([illegible]
DT Warren (Vancouver), DB Sinclair (Edmonton), JD McKean (Edmonton), M Javidan (Vancouver)*

([illegible]
T Akiyama (Toronto), A Ochi (Toronto), D Chan (Toronto), SK Weiss (Toronto), OC Snead III (Toronto), JT Rutka (Toronto), J Drake (Toronto), H Otsubo (Toronto)*

([illegible]
*B Nadler (Montréal), M Shevell (Montréal)**

([illegible]
JY Jiang (London), LC Ang (London), WT Blume (London)*

([illegible]
A Reid (Calgary), N Jetté (Calgary), H Quan (Calgary), M Hill (Calgary), S Wiebe (Calgary)*

Victoria
British Columbia

(-[illegible] %[illegible]

SK Balagopal (London), RS McLachlan (London), S Brown (London), BH Abello (London), PA Derry (London)*

(-[illegible] ([illegible]

AM Al-Kaabi (Winnipeg), N Yahmad (Winnipeg), AE Yankovsky (Winnipeg), Y Aghakhani (Winnipeg)*

(-[illegible] [illegible]*IS1* [illegible]

A Mineyko (Ottawa), KM Boycott (Ottawa), A Doja (Ottawa)*

(-[illegible] [illegible]

R RamachandranNair (Hamilton), K Parameswaran (Hamilton)*

(-[illegible] [illegible]

RW Dudley (Montréal), SJ Penney (St. John's), D Buckley (St. John's)*

(-[illegible] [illegible]

RM Sadler (Halifax), SR Rahey (Halifax)*

(-[illegible] ([illegible]

*R RamachandranNair (Hamilton)**

(-[illegible]

L Hamiwka (Calgary), J Loney (Edmonton), E Sherman (Calgary), E Wirrell (Rochester)*

(-[illegible]

P- Bahrami (Khorramabad), Z Farhangian (Khorramabad)*

(-[illegible] ([illegible]

NY Yahmad (Winnipeg), A Al-Kaabi (Winnipeg), A Yankovsky (Winnipeg), Y Aghakhani (Winnipeg)*

(-[illegible]

R RamachandranNair (Hamilton), M Zaazou (Hamilton), GM Ronen (Hamilton)*

(-[illegible]

L Carmant (Montréal), A Elie (Port-Au-Prince), M Sévère (Port-Au-Prince), D Santos-Viloria (Santo Domingo), D Rivera (Santo Domingo)*

(-[illegible] &[illegible]

JG Barnes (Winnipeg), Y Aghakhani (Winnipeg), AE Yankovsky (Winnipeg)*

(-[illegible]

S Perreault (Montréal), E Boudes (Montréal), P Diadori (Montréal), D Nguyen (Montréal), P Major (Montréal), Y Patenaude (Sherbrooke), Y Boulanger (Montréal), L Carmant (Montréal)*

(-[illegible]

P Afra (Salt Lake City), MB Johnson (Salt Lake City), JE Warner (Salt Lake City), T Constantino (Salt Lake City), F Matsuo (Salt Lake City), JS Anderson (Salt Lake City), M Funke (Salt Lake City)*

(-[illegible]

M Sharpe (London), L Norton (London), C Davies-Schinkel (London), B Young (London)

(-[illegible]

SM Mirsattari (London), FA Alotaibi (London), SW Wang (Los Angeles), J Shoemaker (London), RE Martin (London), A Parrent (London)*

(-[illegible]

JF Tellez Zenteno (Saskatoon), GR Hunter (Saskatoon), S Wiebe (Calgary)*

(-[illegible]

LM Bateman (Sacramento), M Seyal (Sacramento)*

(-[illegible]

AP Masiowski (Saskatoon), JF Tellez-Zenteno (Saskatoon), V Sadanand (Saskatoon), M Vrbancic (Saskatoon)*

(-[illegible] %[illegible]

WJ Hader (Calgary), EM Sherman (Calgary), T Williams (Calgary), HB Sarnat (Calgary), L Hamiwka (Calgary), I Mohamed (Calgary), S Wiebe (Calgary)*

(-[illegible] &[illegible]

AF Almulla (Winnipeg), O Williams (Winnipeg), AE Yankovsky (Winnipeg), Y Aghakhani (Winnipeg)*

[illegible]

(-[illegible] [illegible]
*EM Al-Khateeb (Amman)**

(-[illegible] [illegible]
M Mehdizadeh (Tehran), B Ebadi (Tehran), A Nahavandi (Tehran)*

(-[illegible] [illegible]
DH Zhang (Hamilton), NK Murty (Hamilton)*

(-[illegible] [illegible]
Y Lee (Tainan), P Pao (Tainan), W Chang (Tainan)*

(-[illegible] [illegible]
JA McCombe (Edmonton), MJ Narayansingh (Edmonton), JH Jhamandas (Edmonton)*

(-[illegible] [illegible]
AM Al-Kaabi (Winnipeg), JL Johnston (Winnipeg), AE Yankovsky (Winnipeg)*

(-[illegible] [illegible]
N Steffenhagen (Calgary), I Dzialowski (Dresden), V Puetz (Dresden), C O'Reilly (Calgary), A Demchuk (Calgary)*

(-[illegible] [illegible]
M Horton (Winnipeg), AE Yankovsky (Winnipeg), Y Agha-Khani (Winnipeg)*

(-[illegible] [illegible]
MK Demos (Vancouver), T Fullston (Adelaide), J Gecz (Adelaide), W Gibson (Vancouver)*

(-[illegible] [illegible]
*MP Namaka (East St. Paul)**

(-[illegible] [illegible]
JY CHU (Toronto), A Evans (Toronto)*

(-[illegible] [illegible]
AM Al-Kaabi (Winnipeg), R Yanofsky (Winnipeg), M Bunge (Winnipeg), J Hyman (Winnipeg), M Rafay (Winnipeg)*

(-[illegible] [illegible]
KM Sauro (Calgary), WJ Becker (Calgary)*

(-[illegible] [illegible]
KM Sauro (Calgary), WJ Becker (Calgary), SN Christie (Ottawa), R Giammarco (Hamilton), GF Mackie (Richmond), AG Eloff (Calgary), MJ Gawel (Toronto)*

(-[illegible] [illegible]
TE Gofton (London), MS Jog (London), V Schulz (London)*

(-[illegible] [illegible]
*WJ Becker (Calgary)**

(-[illegible] [illegible]
N Chaudhary (Hamilton), F Martha (Hamilton), N Shalini (Hamilton)*

(-[illegible] [illegible]
TA Alwasaidi (Halifax), S Kirby (Halifax), G Shanmugam (Halifax), B Kent (Halifax), R Baskett (Halifax)*

(-[illegible] [illegible]
S Kalra (Edmonton), R Camicioli (Edmonton), M Lynch (Edmonton), W Johnston (Edmonton), N Fisher (Edmonton), P Seres (Edmonton), C Choi (Dallas)*

(-[illegible] [illegible]
JA Pettersen (Toronto), SE Black (Toronto), S Naqvi (Toronto), S Jin (Toronto), BJ Murray (Toronto)*

(-[illegible] ([illegible]

DM Andrade (Toronto), SW Scherer (Toronto), BA Minassian (Toronto)*

(-[illegible] [illegible]

S O.K (Vancouver), J Stoessl (Vancouver), G Gibson (Vancouver), E Mac (Vancouver)*

(-[illegible] [illegible]

A Rana (Toronto), F Khan (Toronto)*

(-[illegible] [illegible] ***Cryptococcus gattii*** [illegible]

ME Sharp (Vancouver), P Phillips (Vancouver), KM Chapman (Vancouver)*

(-[illegible] [illegible]

*L Boissé (Kingston), K Kimpinski (Rochester), PR Bourque (Ottawa), CF Bolton (Kingston)**

(-[illegible] ([illegible]

G Pfeffer (Vancouver), AT Vertinsky (Vancouver), JJ Barton (Vancouver)*

(-[illegible] [illegible]

JA Sharpe (Toronto), J Kang (Toronto)*

(-[illegible] [illegible]

S ThayaparaRaj (London),I Gulka (London), A Al Amri (London), S Das (London), B Young (London)

(-[illegible] . [illegible]

JA Sharpe (Toronto), MS Salman (Winnipeg), L Lillakas (Toronto), M Dennis (Toronto), MJ Steinbach (Toronto)*

(-[illegible] [illegible]

U Ramanathan (Edmonton), C Power (Edmonton), L Resch (Edmonton), L Saxinger (Edmonton)*

(-[illegible] [illegible]

SK Baker (Hamilton), S Vernino (Dallas), C Morillo (Hamilton)*

(-[illegible] [illegible]

CE Diesta (Calgary), S Edworthy (Calgary), O Suchowersky (Calgary)*

(-[illegible] [illegible]

T Smart (Winnipeg), J Helps (Winnipeg), K Sabalvaro (Winnipeg), D Hobson (Winnipeg)*

(-[illegible] [illegible]

A Mendez (Halifax), I Grant (Halifax)*

(-[illegible] [illegible]

OA Ayoub (Vancouver), N Kandiah (Vancouver)*, H Feldman (Vancouver)*

(-[illegible] [illegible]

N Makhani (Toronto), SK Morris (Toronto), J Brophy (Toronto), B Banwell (Toronto)*

(-[illegible] ([illegible]

SK Baker (Hamilton), AF Hahn (London), S Raha (Hamilton), PJ Ainsworth (London)*

(-[illegible] [illegible]

SK Baker (Hamilton), PJ Ainsworth (London)*

(-[illegible] [illegible]

JF Tellez-Zenteno (Saskatoon), H Lizbeth (Saskatoon), G Garcia-Ramos (Mexico City), F Zermeño-Pöhls (Mexico City)*

(-[illegible] [illegible]

SN Christie (Ottawa), R Giamarco (Hamilton), W Becker (Calgary), M Gawel (Toronto), G Mackie (Vancouver), J Gladstone (Toronto)*

(-[illegible] [illegible]

LP Hnenny (Saskatoon), SJ Hentschel (Victoria), S Sanche (Saskatoon)*

(-[illegible] [illegible]

*J Zwicker (Ottawa)**

Victoria British Columbia

[illegible]

([illegible] [illegible]
*I Kowalczyk (London),M Fink (London), N Duggal (London)**

([illegible] [illegible]
DT Warren (Vancouver), C Dunham (Vancouver), DD Cochrane (Vancouver)*

([illegible] [illegible]
K Kumar (Regina), V Bodani (Regina), S Tracey (Regina), S Bishop (Regina)*

([illegible] [illegible]
AA Yassin (Hamilton), D Sommer (Hamilton), K Reddy (Hamilton)*

([illegible] [illegible]
*P Gooi (Calgary), K Punja (Calgary), D McPhalen (Calgary), A Clark (Calgary), M Hamilton (Calgary)**

([illegible] [illegible]
NK Jha (Hamilton), S Ebrahim (Toronto), A Fallah (Hamilton), A Cenic (Hamilton), RA De Villiers (Hamilton)*

([illegible] [illegible]
N Chaudhary (Hamilton), P Klurfan (Hamilton), D Sarma (Hamilton), K Reddy (Hamilton)*

([illegible] [illegible]
P Magown (Halifax), PD McNeely (Halifax), W Howes (Halifax)*

([illegible] [illegible]
S Yuh (Ottawa), M Vassilyadi (Ottawa)*

([illegible] [illegible]
M Lee (Hamilton), BW Lo (Hamilton), G Belovay (Hamilton)*

([illegible] [illegible]
B Baronia (Saint Louis), M Vassilyadi (Ottawa)*

([illegible] [illegible]
N McLaughlin (Montréal),A Weill (Montréal), MW Bojanowski (Montréal)

([illegible] [illegible]
N McLaughlin (Montréal), M Laroche (Montréal), MW Bojanowski (Montréal)

([illegible] [illegible]
N McLaughlin (Montréal), F Lavigne (Montréal), S Kilty (Montréal), F Berthelet (Montréal), O Serri (Montréal),
C Beauregard (Montréal), MW Bojanowski (Montréal)

([illegible] [illegible]
C Pinkoski (London), SP Lownie (London)*

([illegible] [illegible]
K Bullivant (Calgary),A Mitha (Calgary), M Hamilton (Calgary)

([illegible] [illegible]
C Dong (Vancouver), R Akagami (Vancouver), B Westerberg (Vancouver)*

([illegible] [illegible]
FE Alotaibi (Riyadh), KN Almusrea (Riyadh)*

([illegible] [illegible]
EM Frangou (Saskatoon), E Schûltke (Saskatoon), K Ataelmannan (Saskatoon), D Chapman (Saskatoon),*
T Wysokinski (Saskatoon), R Griebel (Saskatoon), B Juurlink (Saskatoon), H Taherian (Saskatoon), D Fourney (Saskatoon)

([illegible] [illegible]
EE Dyer (London), S Lownie (London), J Armstrong (London), M McDonald (London)*

([illegible] [illegible]
WJ Hader (Calgary), L Ozen (Calgary), L Hamiwka (Calgary), E Sherman (Calgary)*

Victoria British Columbia

(-[illegible] [illegible]
D Louw (Edmonton), S Brien (Ottawa), R Barrett (Calgary)*

[illegible]

(-[illegible] [illegible]
*K Mukhida (Toronto)**
(-[illegible] [illegible]
*K Mukhida (Toronto)**
(-[illegible] [illegible]
*M del Campo (Toronto)**

[illegible]

(-[illegible] [illegible]
LW Ferguson (Saskatoon), ML Rajput (Saskatoon), A Rajput (Saskatoon)**
(-[illegible] [illegible]
A Lerner (Bethesda), A Bagic (Pittsburgh), Z Mari (Baltimore), JA Simmons (Bethesda), AC Nugent (Bethesda), B Xu (Bethesda), R Carson (New Haven,), WC Drevets (Bethesda), DL Murphy (Bethesda), M Hallett (Bethesda)*
(-[illegible] [illegible]
A Samii (Seattle), M Etminan (Vancouver)*
(-[illegible] [illegible]
A Rana (Toronto), F Khan (Toronto)*
(-[illegible] [illegible]
A Rana (Toronto), F Khan (Toronto)*
(-[illegible] [illegible]
A Rana (Toronto), F Khan (Toronto)*
(-[illegible] [illegible]
D Hobson (Winnipeg), J Tsui (Vancouver), D King (Halifax), M Jog (London), The Canadian Movement Disorder Study Group (Toronto)*
(-[illegible] [illegible]
A Rana (Toronto), F Knan (Toronto)*
(-[illegible] [illegible]
R Laforce (Quebec), J Bouchard (Quebec), N Dupré (Quebec), C Berthelot (Quebec)*
(-[illegible] [illegible]
AO Hebb (Seattle), A Poliakov (Seattle), J Slimp (Seattle), M Ramos (Seattle), A Samii (Seattle)*
(-[illegible] [illegible]
A Al-Futaisi (Muscat), A Al-Mawali (Muscat), R Koul (Muscat), S Al-Yahyai (Muscat)*
(-[illegible] [illegible]
*Karim Mukhida**

[illegible]

([illegible]
SA Warren (Edmonton), KV Turpin (Edmonton), G Wheeler (Edmonton), KG Warren (Edmonton)*

([illegible]
SA Hashimoto (Vancouver), H Tremlett (Vancouver), NJ Ball (Vancouver)

([illegible]
KS Waspe (Langley), G Vorobeychik (Burnaby)*

([illegible]
J Spring (Burnaby), G Vorobeychik (Burnaby), KS Waspe (Burnaby)**

([illegible]
A Sayao (Vancouver), C Hrazdil (Vancouver), C Honey (Vancouver), P Smyth (Vancouver)*

([illegible]
*A Sadovnick (Vancouver), C Guimond (Vancouver), J Kennedy (Toronto), A Bar-Or (Montréal), D Arnold (Montréal), M McGowan (Toronto), B Banwell (Toronto)**

([illegible]
F Jacques (Hull), M Gangal (Mississauga)*

[illegible]

([illegible]
FJ Mateen (Rochester), D van de Beek (Rochester), RC Daly (Rochester), BS Edwards (Rochester), CG McGregor (Rochester), EF Wijdicks (Rochester)*

([illegible]
HM Al-Jehani (Montréal), L Jacques (Montréal)*

([illegible]
JK Mah (Calgary), N Liu (Calgary), M Moore (Calgary)*

([illegible]
A Michoulas (Vancouver), K Selby (Vancouver)*

([illegible]
HJ McMillan (Ottawa), JK Mah (Calgary), C Campbell (London)*

([illegible]
A Kirton (Calgary), C Gunraj (Toronto), R Chen (Toronto)*

([illegible]
KL Schellenberg (Edmonton), L Resch (Edmonton), S Kalra (Edmonton), ES Johnson (Edmonton), WS Johnson (Edmonton)*

([illegible]
A Dionne (London), A Parkes (London), E Beata (London), W Bradley (London), MW Nicolle (London)*

([illegible]
*A Rana (Toronto)**

([illegible]
JL Bouchard (Quebec City), M Tétreault (Montréal), M Srour (Montréal), J Allyson (Montréal), I Thiffault (Montréal), L Loisel (Montréal), Y Robitaille (Montréal), M Vanasse (Montréal), B Bernard Brais (Montréal)*

([illegible]
*R Abdwani (Muscat), K Roshan (Muscat), Jain (Muscat), A Al-Futaisi (Muscat)**

(-[illegible] [illegible]
(□%□&-X□
MJ Esser (Calgary), JK Mah (Calgary), HB Sarnat (Calgary), K Barlow (Calgary)*

(-[illegible] [illegible]
ET Payne (Calgary), JK Mah (Calgary), HB Sarnat (Calgary)*

(-[illegible] [illegible]
SL Venance (London), KA LaDonna (London), WJ Koopman (London), B Engler (London), K Findlater (London), AF Hahn (London)*

(-[illegible] [illegible]
*SK Baker (Hamilton)**

(-[illegible] [illegible]
CL Phan (Edmonton), D Poppe (Edmonton), J Smallhorn (Edmonton), J Dyck (Edmonton), D Patton (Calgary), J Harder (Calgary), J Mah (Calgary), R Rosychuk (Edmonton), HK Kolski (Edmonton)*

(-[illegible] [illegible]
H Rahgig (London), R Hammond (London), M Nicolle (London), B Young (London)

[illegible]

(-[illegible] [illegible]
A Szymczak (London), AM Ranger (London), S Zelcer (London), R Hammond (London)*

(-[illegible] [illegible]
P Durand-Martel (Sherbrooke), A Guillemette (Sherbrooke)*, S Gosselin (Sherbrooke), A Tsanaclis (Sherbrooke), D Mathieu (Sherbrooke), N Dea (Sherbrooke)*

(-[illegible] [illegible]
T Rajapakse (Calgary), JK Mah (Calgary), V Lewis (Calgary), CL Trevenen (Calgary), X Wei (Calgary), HB Sarnat (Calgary)*

(-[illegible] [illegible]
M West (Winnipeg), F Iqbal (Winnipeg), A Kaufmann (Winnipeg), D Fewer (Winnipeg), G Schroeder (Winnipeg)*

(-[illegible] [illegible]
FB Maroun (St. John's), R Avery (St. John's), GP Murray (St. John's), K Hong (St. John's), JC Jacob (St. John's), J Barron (St. John's), A Norman (St. John's)*

(-[illegible] [illegible]
B Hassouneh (Winnipeg), J Nesbitt (Winnipeg), G Schroeder (Winnipeg), D Fewer (Winnipeg), A Kaufmann (Winnipeg), M West (Winnipeg)*

(-[illegible] [illegible]
A Singhal (Vancouver), K Pakzad-Vaezi (Vancouver), DD Cochrane (Vancouver), M Sargeant (Vancouver)*

(-[illegible] [illegible]
E Dyer (London),JF Megyesi (London), W McDonald (London), D Macdonald (London), R Hammond (London), P Costello (London)

(-[illegible] [illegible]
A Singhal (Vancouver), J Hukin (Vancouver), T Ailon (Vancouver)*

(-[illegible] [illegible]
S Chhibber (Calgary), C White (Calgary)*

(-[illegible] [illegible]
T Ailon (Vancouver), J Hukin (Vancouver), S Yip (Vancouver), T Yamashita (Vancouver), M Sargent (Vancouver), A Singhal (Vancouver), C Fryer (Vancouver), G Hendson (Vancouver), K Goddard (Vancouver)*

[illegible]

(-[illegible] [illegible]

MF Shamji (Ottawa), L Selznick (Durham), RE Isaacs (Durham)*

(-[illegible] [illegible]

MF Shamji (Ottawa), A Perry (St. Louis), G Jansen (Ottawa), B Benoit (Ottawa)*

(-[illegible] [illegible]

K Kumar (Regina), R Nguyen (Regina)*

(-[illegible] [illegible]

MF Shamji (Ottawa), P Hwang (Durham), L Jing (Durham), J Chen (Durham), AH Friedman (Durham), WJ Richardson (Durham), LA Setton (Durham)*

(-[illegible] [illegible]

GS McLoughlin (Saskatoon), RW Griebel (Saskatoon), S Seshia (Saskatoon)*

(-[illegible] [illegible]

L Ogieglo (Saskatoon), E Frangou (Saskatoon), S Hentschel (Victoria), D Fourney (Saskatoon)*

(-[illegible] [illegible]

L Ogieglo (Saskatoon), S Hentschel (Victoria), R Fox (Edmonton), D Fourney (Saskatoon)*

(-[illegible] [illegible]

A Iloreta (Calgary), J Sarna (Calgary), P Sharma (Calgary), G Klein (Calgary)*

(-[illegible] [illegible]

F Moien-Afshari (Saskatoon), M Machnowska (Saskatoon), S Wiebe (Saskatoon), C Voll (Saskatoon)*

(-[illegible] [illegible]

M Vassilyadi (Ottawa), S Yuh (Ottawa), T Trigylidas (Ottawa), M Matzinger (Ottawa)*

(-[illegible] [illegible]

HM Al-Jehani (Montréal), K Petrecca (Montréal), J Hall (Montréal), L Jacques (Montréal), DJ Sirhan (Montréal)*

(-[illegible] [illegible]

M Laroche (Montréal), M Audet (Montréal), A Weil (Montréal), D Shedid (Montréal)*

(-[illegible] [illegible]

F Alkherayf (Ottawa), A Alali (Ottawa), B Benoit (Ottawa), J Sinclair (Ottawa), A Berthiaume (Ottawa), E Olairu (Ottawa), I Cameron (Ottawa), E Tsai (Ottawa)*

(-[illegible] [illegible]

PK Singh (Sheffield), S Gupta (New Delhi), V Singh (New Delhi), J Tomar (New Delhi)*

(-[illegible] [illegible]

JD Souster (Edmonton), R Broad (Edmonton)*

(-[illegible] [illegible]

MA Riesberry (Saskatoon), K Meguro (Saskatoon), H Ward (Saskatoon)*

(-[illegible] [illegible]

*RJ Diaz (Calgary)**

(-[illegible] [illegible]

L Yang (Gold Coast), P Blumbergs (Adelaide), N Jones (Adelaide)*

(-[illegible] [illegible]

L Yang (Gold Coast), P Blumbergs (Adelaide), N Jones (Adelaide)*

(-[illegible]

SH Lwu (Calgary), KC Thomas (Calgary), RJ Hurlbert (Calgary)*

(-[illegible]

N Chaudhary (Brampton), B Chris (London)*

(-[illegible]

R Murphy (Halifax),G Thibault-Halman (Halifax), SD Christie (Halifax)

(-[illegible]

K Aal-Ali (Halifax), SD Christie (Halifax)

(-[illegible]

JJ Shankar (Ottawa), MK Vasudev (Bangalore), S Ravishankar (Bangalore), PN Jayakumar (Bangalore)*

(-[illegible]

*R Sahjpaul (North Vancouver)**

(-[illegible]

D Tampieri (Montréal), H Al-Jehani (Montréal), J Farmer (Montréal)*

[illegible]

(-[illegible]

DT Warren (Vancouver), M Heran (Vancouver), CS Haw (Vancouver), P Steinbok (Vancouver)*

(-[illegible]

ML Miley (Chicago), BJ Bobrow (Phoenix), BM Demaerschalk (Phoenix)*

(-[illegible]

ML Miley (Chicago), BJ Bobrow (Phoenix), BM Demaerschalk (Phoenix)*

(-[illegible]

MP Dos Santos (Ottawa), L Deus-Silva (Ottawa), S Chakraborty (Ottawa), B Schwarz (Ottawa), HJ Lesiuk (Ottawa), W Miller (Ottawa), MS Kingstone (Ottawa), T Nguyen (Ottawa), C Lum (Ottawa)*

(-[illegible]

MP Dos Santos (Ottawa), R Mohan (Ottawa), L Deus-Silva (Ottawa), S Chakraborty (Ottawa), HJ Lesiuk (Ottawa), B Schwarz (Ottawa), C Lum (Ottawa)*

(-[illegible]

WJ Logan (Toronto), JS Han (Toronto), J Poublanc (Toronto), D Armstrong (Toronto), M Shroff (Toronto), JA Fisher (Toronto), DJ Mikulis (Toronto), PB Dirks (Toronto), G deVeber (Toronto)*

(-[illegible]

CT Hrazdil (Vancouver), A Stoessl (Vancouver)*

(-[illegible]

M Labib (London), SP Lownie (London), D Pelz (London)*

(-[illegible]

*F Guilbert (Montréal), S Lanthier (Montréal)**

(-[illegible]

A Aljishi (Montreal), M Maleki (Montréal)*

(-[illegible]

EA Macdonald (Kingston), C Curtis (Kingston)**

(-[illegible]

A Michoulas (Vancouver), MK Heran (Vancouver), DA Graeb (Vancouver), E Shereck (Vancouver), K Poskitt (Vancouver), A Woolfenden (Vancouver), J Hukin (Vancouver)*

(-[illegible]

*Y Kim (Cheonan)**

Victoria British Columbia

(-[illegible] %[illegible]

J Warman (Ottawa), M Sharma (Ottawa)*

(-[illegible] [illegible]

K Petrecca (Montréal), D Sirhan (Montréal)**

(-[illegible] [illegible]

JB Chew (Montréal), A Weill (Montréal), F Guilbert (Montréal), J Raymond (Montréal), M Audet (Montréal), D Roy (Montréal)*

(-[illegible] [illegible]

N McLaughlin (Montréal),M Lévêque (Montréal), MW Bojanowski (Montréal)

(-[illegible] [illegible]

O Beaudoin (Montréal),M Lévêque (Montréal), N McLaughlin (Montréal), I Saliba (Montréal), MW Bojanowski (Montréal)

(-[illegible] [illegible]

N McLaughlin (Montréal), M Lévêque (Montréal), MW Bojanowski (Montréal)

(-[illegible] [illegible]

N McLaughlin (Montréal), P Bourgouin (Montréal), MW Bojanowski (Montréal)*

(-[illegible] ([illegible]

MC Ng (St. John's), D Emery (Edmonton), E Yacyshyn (Edmonton)*

(-[illegible] [illegible]

AY Poppe (Calgary), SB Coutts (Calgary), JC Kosior (Calgary), MD Hill (Calgary), CM O'Reilly (Calgary), AM Demchuk (Calgary)*

(-[illegible] [illegible]

SH Khan (Cincinnati), CW Nichols (Cincinnati), JJ DePowell (Cincinnati), TA Abruzzo (Cincinnati), AJ Ringer (Cincinnati)*

(-[illegible] %[illegible]

R Agid (Toronto), K Terbrugge (Toronto), G Rodesch (Paris), T Andersson (Stockholm), M Söderman (Stockholm)*

(-[illegible] [illegible]

M Vassilyadi (Ottawa), J Michaud (Ottawa)*

(-[illegible] [illegible]

FB Maroun (St. John's), A Engelbrecht (St. John's), G Fox (St. John's)*

(-[illegible] [illegible]

G Pfeffer (Vancouver), MS Heran (Vancouver)*

(-[illegible] %[illegible]

SH Khan (Cincinnati), O Adeoye (Cincinnati), TA Abruzzo (Cincinnati), LA Shutter (Cincinnati), AJ Ringer (Cincinnati)*

(-[illegible] [illegible]

L Thines (Toronto), AR Dehdashti (Toronto), L Da Costa (Toronto), M Tymianski (Toronto), KG TerBrugge (Toronto),*
M Schwartz (Toronto), RA Willinsky (Toronto), C Wallace (Toronto)

(-[illegible] [illegible]

*H Al Gethami (London), R Novick (London), A Al Amri (London), D Nicolle (London), B Young (London)**

(-[illegible] ([illegible]

CC Dueck (Winnipeg), DD Eisenstat (Winnipeg), D Grynspan (Winnipeg), F Qureshi (Detroit), MF Rafay (Winnipeg)*

(-[illegible] [illegible]

SH Khan (Cincinnati), TA Abruzzo (Cincinnati), O Choutka (Cincinnati), A Losinieki (Cincinnati), AJ Ringer (Cincinnati)*

(-[illegible] %[illegible]

N Gelinas-Phaneuf (Montréal), DJ Sirhan (Montréal)*

(-[illegible] [illegible]

SH Khan (Cincinnati), TA Abruzzo (Cincinnati), AJ Ringer (Cincinnati)*

(-[illegible] [illegible]

SH Khan (Cincinnati), A Grande (Cincinnati), S Parikh (Cincinnati), F Hui (Atlanta), M Zuccarello (Cincinnati), JE Dion (Atlanta), FC Tong (Atlanta), M Cawley (Atlanta), AJ Ringer (Cincinnati), TA Abruzzo (Cincinnati)*

(-[illegible] [illegible]

LB da Costa (Toronto), L Thines (Toronto), A Dehdashti (Toronto), MC Wallace (Toronto), RA Willinsky (Toronto), M Schwartz (Toronto), M Tymianski (Toronto), KG ter Brugge (Toronto)*

(-[illegible] [illegible]

LB da Costa (Toronto), TR Marotta (Toronto), W Montanera (Toronto), J Spears (Toronto)*

(-[illegible] [illegible]

LB da Costa (Toronto), MQ Ribeiro (Braga), PR Howard (Toronto), RA Willinsky (Toronto), KG ter Brugge (Toronto)*

(-[illegible] [illegible]

NS Alshafai (Toronto), M Cusimano (Toronto), S Ho (Toronto)*

(-[illegible] [illegible]

EJ Versnick (Halifax), R Vandorpe (Halifax), D Kydd (Halifax), I Fleetwood (Halifax), W Maloney (Halifax)*

(-[illegible] [illegible]

CD Harraher (Boston), C Dawson (Boston), I Fleetwood (Boston), G Gubitz (Boston), C Christian (Boston), G MacKean (Boston), S Phillips (Boston)*

(-[illegible] [illegible]

JR Sarna (Calgary), A Iloreta (Calgary), P Sharma (Calgary), G Klein (Calgary)*

[illegible]

(-[illegible] [illegible]

*M Movassat (Tehran)**

(-[illegible] [illegible]

CH Tator (Toronto), M Wan (London), H Nomura (Fukuoka)*

(-[illegible] [illegible]

N Zwiers (London), L Pearlman (London), C Campbell (London)*

(-[illegible] [illegible]

M Mrazik (Edmonton), D Louw (Edmonton)*

(-[illegible] [illegible]

E Kouznetsov (Ottawa), M Brennan-Barnes (Ottawa), M Vassilyadi (Ottawa)*

Victoria British Columbia

[illegible]

[illegible]

The Victoria Conference Centre
720 rue Douglas
Victoria (C,-B.) V8W 3M7

[illegible]

K[illegible]
Victoria Conference Centre

Mardi 17 juin	de 7h30 à 18h30
Mercredi 18 juin	de 7h à 18h30
Jeudi 19 juin	de 7h à 18h30
Vendredi 20 juin	de 7h à 13h30

[illegible]

Du 9 au 12 juin 2009	Halifax, Nouvelle-Écosse
Du 8 au 11 juin 2010	Québec, Québec

[illegible]

- Les participants inscrits pour l'événement entier peuvent assister à toutes les séances du congrès annuel 2008, du mardi 17 juin au vendredi 20 juin.
- Comprend la réception des conférenciers.

[illegible]

- Les participants inscrits pour une journée peuvent assister à toutes les séances qui ont lieu ce jour-là. Comprend également la réception des conférenciers du mercredi ou le dîner dans le hall d'exposition le jeudi ou le vendredi, si vous êtes inscrit pour ces jours-là.

[illegible]

- Les délégués doivent porter leur insigne en tout temps afin d'accéder aux cours, aux séances scientifiques et aux soirées du congrès. Des billets seront exigés pour la réception du président.

É. [illegible]

[illegible]

Mardi 17 juin 2008 - de 7 h 15 à 8 h 15
Victoria Conference Centre - Tous les résidents sont invités à participer à ce déjeuner et à rencontrer leurs collègues ainsi que les membres du conseil d'administration de la FSNC. Déjeuner continental gratuit.

[illegible]

Mercredi 18 juin 2008 - de 17 h 30 à 19 h
Victoria Conference Centre - Hall Carson
Vin et fromage. Bar payant. [illegible]

[illegible]

Jeudi 19 juin 2008 - de 17 h 30 à 19 h
Victoria Conference Centre Bavardez avec vos amis et collègues. Code vestimentaire d'affaires en vigueur. Hors-d'œuvre et deux billets gratuits pour deux boissons; bar payant par la suite. Ceci est l'événement mondain principal du congrès. Seuls des hors-d'œuvre seront servis; il ne s'agit pas d'un souper, et cet événement n'est pas compris dans l'inscription. Tous les participants doivent se procurer des billets au prix de 35 $. Ceux-ci devront être présentés à l'entrée.

Objectifs éducatifs du congrès 2008 :

À la fin du congrès, les participants sauront :

- **Discuter des progrès réalisés dans le diagnostic et le traitement des affections neurologiques aiguës et chroniques**
- **Examiner les nouvelles solutions de traitement disponibles pour les affections nécessitant une neurochirurgie**
- **Résumer les progrès réalisés en neurobiologie de la douleur chronique**
- **Décrire les défis inhérents au diagnostic et au traitement des maladies enzymatiques**

[illegible]

07:00-18:00 Salle de préparation pour les conférenciers
Salle Metchosin, Conference Centre

07:15-08:15 Déjeuner des résidents
Salle Saanich, Conference Centre

07:30-18:30 Inscription
Region de inscription, Conference Centre

08:30-17:00 [illegible]
Lecture Theatre, Conference Centre

08:30-17:00 [illegible] *Salle Oak Bay, Conference Centre*

08:30-17:00 [illegible]
Crystal Ballroom, Empress

12:15-13:00 Dîner SLA
Salle Saanich, Conference Centre

18:00-20:00 [illegible]
Lecture Theatre, Conference Centre

18:00-20:00 [illegible]
Salle Oak Bay, Conference Centre

[illegible]

07:00-18:00 Salle de préparation pour les conférenciers
Salle Metchosin, Conference Centre

07:00-18:30 Inscription
Region de inscription, Conference Centre

08:30-10:30 [illegible]
Lecture Theatre, Conference Centre

10:30-10:45 Pause *Foyer, Conference Centre*

10:45-12:15 [illegible]
Lecture Theatre, Conference Centre

12:30-14:00 [illegible] ***Élaboration conjointe***
Crystal Ballroom, Empress

12:30-14:00 [illegible] ***Élaboration conjointe***
Salle Saanich, Conference Centre

14:00-17:30 [illegible]
Salle Sidney, Conference Centre

14:00-17:30 [illegible]
Lecture Theatre, Conference Centre

14:00-17:30 [illegible]
Salle Buckingham, Empress

14:00-17:30 [illegible] *Oak Bay 2, Conference Centre*

14:00-17:30 [illegible]
Oak Bay 1, Conference Centre

14:00-17:30 [illegible]
Salle Esquimalt, Conference Centre

17:30-19:00 Ouverture de l'exposition - Réception des conférenciers *Carson Hall, Conference Centre*

[illegible]

07:00-18:00 Salle de préparation pour les conférenciers
Salle Metchosin, Conference Centre

07:30-18:30 Inscription
Region de inscription, Conference Centre

08:30-10:00 [illegible]
Lecture Theatre, Conference Centre

08:30-10:00 [illegible] *Salle Saanich, Conference Centre*

10:00-10:15 Pause *Carson Hall, Conference Centre*

10:15-12:30 [illegible]
Lecture Theatre, Conference Centre

10:15-12:30 [illegible]
Salle Sidney, Conference Centre

10:15-12:30 [illegible]
Oak Bay 1, Conference Centre

10:15-12:30 [illegible]
Oak Bay 2, Conference Centre

10:15-12:30 [illegible]
Salle Esquimalt, Conference Centre

Victoria British Columbia

10:15-12:30 [illegible] *Salle Saanich, Conference Centre*

10:15-12:30 [illegible] *Salle Colwood, Conference Centre*

12:30-14:00 Dîner / Visite de l'exposition / Visionnement des affiches *Carson Hall, Conference Centre*

14:00-16:30 [illegible] *Lecture Theatre, Conference Centre*

14:00-16:30 [illegible] *Oak Bay 1, Conference Centre*

14:00-16:30 [illegible] *Salle Saanich, Conference Centre*

14:00-16:30 [illegible] *Oak Bay 2, Conference Centre*

14:00-16:30 [illegible] *Salle Esquimalt, Conference Centre*

14:00-16:30 [illegible] *Salle Sidney, Conference Centre*

14:00-16:30 [illegible] *Salle Colwood, Conference Centre*

16:30-17:30 Visionnement des affiches numériques et visite de l'exposition *Carson Hall, Conference Centre*

17:30-19:00 Réception du président *Courtyard, Conference Centre*

[illegible]

07:00-14:30 Salle de préparation pour les conférenciers *Salle Metchosin, Conference Centre*

07:00-13:30 Inscription *Region de inscription, Conference Centre*

08:30-09:30 [illegible] *Lecture Theatre, Conference Centre*

09:30-09:45 Présentation du Prix Eminent relecteur de manuscrits *Lecture Theatre, Conference Centre*

09:45-10:00 Rapport de journal *Lecture Theatre, Conference Centre*

09:45-10:15 Pause et visite de l'exposition *Carson Hall, Conference Centre*

10:15-12:00 [illegible] *Lecture Theatre, Conference Centre*

12:00-13:30 Dîner / Visite de l'exposition / Visionnement des affiches *Carson Hall, Conference Centre*

13:30-17:00 [illegible] *Salle Saanich, Conference Centre*

13:30-17:00 [illegible] *Oak Bay, Conference Centre*

13:30-17:00 [illegible] *Salle Esquimalt, Conference Centre*

13:30-17:00 [illegible] *Salle Colwood, Conference Centre*

13:30-17:00 [illegible] *Salle Sidney, Conference Centre*

13:30-17:00 [illegible] *Lecture Theatre, Conference Centre*

13:30-17:00 [illegible] *Crystal Ballroom, Empress*

[illegible]

Assemblée générale annuelle (AGA)
Association canadienne de neurologie pédiatrique (ACNP)
Federation des sciences neurologiques du Canada (FSNC)
Journal canadien des sciences neurologiques (Journal)
Société canadienne de neurologie (SCN)
Société canadienne de neurochirurgie (SCNCH)
Société canadienne de neurophysiologie clinique (SCNC)
Fondation des sciences neurologiques du Canada (FSNC)
Le type audacieux montre des événements de programme scientifiques.
Affaires de spectacles non-audacieuses et d'autres événements.

Victoria British Columbia

[illegible]

11:00-12:00 Séance du comité de la FSNC - Gouvernance
Salle Buckingham, Empress

12:00-15:00 Séance du comité de la FSNC - Planification et rapports *Salle Buckingham, Empress*

15:00-16:00 Séance du conseil de la Fondation des sciences neurologiques du Canada
Salle Buckingham, Empress

16:00-17:00 Séance du conseil de la FSNC
Salle Buckingham, Empress

17:30-18:30 Séance du conseil de l'ACNP
Salle Kensington, Empress

17:30-19:00 CAN/FSNC 2010 réunion
Salle Buckingham, Empress

[illegible]

09:00-11:00 Séance du comité de développement professionnel de la FSNC
Salle Sidney, Conference Centre

10:00-12:00 Séance du comité du programme scientifique de la FSNC
Salle Sidney, Conference Centre

12:00-13:00 Séance du comité de la section EMG de la SCNC
Salle Buckingham, Fairmont

12:00-13:30 Reunion des résidents en neurologie
Salle View Royal, Conference Centre

13:00-14:00 Séance du comité de la section EEG de la SCNC
Salle Buckingham, Empress

13:00-14:00 Séance du comité de rédaction du journal
Salle Balmoral, Empress

14:00-15:00 Séance du comité de publication du journal
Salle Buckingham, Empress

16:30-18:00 Séance du conseil de la SCNC
Salle Buckingham, Empress

16:30-18:00 Séance du conseil de la SCNCH
Salle Balmoral, Empress

16:30-17:30 Séance d'affaires des résidents en neurochirurgie
Colwood 1, Conference Centre

17:00-18:00 ACNP Assemblée générale annuelle
Crystal Ballroom, Empress

18:00-20:00 Réunion SIG Neuromusculaire
Salle Saanich, Conference Centre

[illegible]

07:30-08:30 Réunion de la Ligue canadienne contre l'épilepsie
Salle Kensington, Empress

07:30-08:30 Réunion AETC *Colwood 1, Conference Centre*

[illegible]

07:00-08:30 Séance du Canadian Board of Registration of EEG Technologists (Conseil canadien d'accréditation des technologues en électroencéphalographie)
Salle Balmoral, Empress

07:30-08:30 Réunion des sociétés affiliées de la FSNC
Salle Kensington, Empress

07:00-08:30 SCN Réunion du conseil
Salle Windsor, Empress

12:30-13:30 Group canadien des soins d'urgence en neurologie
Windsor Room, Fairmont

12:30-13:30 SCN Fondation Séance du conseil
Salle View Royal, Conference Centre

13:00-14:00 Groupe de recherche canadien sur les maladies neuromusculaires pédiatriques
Salle Kensington, Empress

17:00-18:00 SCN Assemblée générale annuelle
Salle Balmoral, Empress

[illegible]

07:00-08:30 SCNC Assemblée générale annuelle
Salle Sidney, Conference Centre

07:00-08:30 SCNCH Assemblée générale annuelle
Salle Colwood, Conference Centre

09:30-10:30 Coalition canadienne pour la santé du cerveau et des nerfs *Salle View Royal, Conference Centre*

10:30-12:00 Groupe canadian de recherche neuromusculaire pediatrique *Salle View Royal, Conference Centre*

12:00-13:00 Groupe canadien neuromusculaire
Salle View Royal, Conference Centre

12:00-13:15 Canadian Headache Society Assemblée générale annuelle *Salle Windsor, Empress*

12:00-13:00 Royal College Committee Neurosurgery
Salle Buckingham, Empress

17:00-18:00 Séance du conseil de la FSNC
Salle View Royal, Conference Centre

17:00-22:00 Séance du Canadian Headache Outpatient & Database Group (Projet canadien de base de données pour les patients externes souffrant de céphalées)
Salle Windsor, Empress

[illegible] *8h30-17h Lecture Theatre, Conference Centre*

Ce cours est rendu possible par une généreuse subvention éducative sans restriction de la Fondation société canadienne de neurologie

[illegible] Peter Smith

[illegible] ce cours portera sur la douleur chronique. Le corps professoral l'utilisera en tant que structure pour l'examen de divers aspects de la neurophysiologie, de la neuropharmacologie et de la neuroanatomie. Notre objectif est de pouvoir fournir des renseignements « du laboratoire au chevet du patient » dans un contexte pertinent à la pratique clinique. Nous voulons montrer la façon dont les procédures de traitement de la douleur fonctionnent et les raisons pour lesquelles certaines d'entre elles ne sont pas efficaces universellement. Nous inclurons également des présentations sur la biologie de la cellule gliale et sur la génétique (canalopathies), en lien avec la discussion générale sur la douleur chronique.

[illegible] À la fin de cette séance, les participants

1) comprendront mieux la façon dont les procédures de traitement de la douleur fonctionnent et les raisons pour lesquelles certaines d'entre elles ne sont pas efficaces universellement.
2) seront au courant des progrès récents réalisés dans la compréhension de l'étiologie de la douleur neuropathique et comprendront en quoi ces progrès mènent à de nouvelles approches thérapeutiques.
3) acquerront de nouvelles connaissances au sujet de l'évaluation de la douleur et des protocoles de traitement de la douleur.
4) approfondiront leurs connaissances de base de la neurobiologie dans un contexte de préparation aux questions d'examen du Conseil.

[illegible] résidents en neurologie, en neurochirurgie et en radiologie

8 h 30 [illegible] ...... *Peter Smith (Edmonton, AB)*

9h15 [illegible] ...... *Jonathan Dostrovsky (Toronto, ON)*

10h15 Discussion et pause

10h45 [illegible] ...... *Matt Wheatley (Edmonton, AB)*

11h30 [illegible] ...... *Yves DeKoninck (Québec, Québec)*

12h15 Discussion

12h45 Dîner

14h00 [illegible] ...... *Peter Light (Edmonton, AB)*

14h45 Discussion

15h15 [illegible] ...... *Ken Craig (Vancouver, C.-B.)*

16h Discussion et évaluation

[illegible] *8h30-17h*

Salle Oak Bay, Conference Centre

[illegible] David Cameron

[illegible] séances interactives toute la journée, qui comprennent une révision complète des thèmes actuels touchant la SLA, y compris le diagnostic et la recherche, le traitement et la sensibilisation.

[illegible] À la fin de ce symposium, les participants sauront :

1) décrire les caractéristiques cliniques et pathophysiologiques actuelles de la SLA.
2) identifier et mettre en pratique des stratégies visant à améliorer l'activité et la qualité de vie des personnes atteintes de SLA.
3) démontrer leur compréhension des initiatives de recherche et des conclusions des études sur la SLA.

[illegible] patients, fournisseurs de soins, professionnels paramédicaux, neurologues, physiatres et agences de soutien communautaire.

8h30 Inscription

9h Accueil .... *David Cameron (Toronto, ON)*

[illegible] – *Présidents: Hannah Briemberg (Vancouver, C.-B.), Sanjay Kalra (Edmonton, AB)*

9h10 [illegible] .... *Neil Cashman (Vancouver, C.-B.)*

9h35 [illegible] .... *Charles Krieger (Vancouver, C.-B.)*

10h Séance de questions et réponses

10h20 Pause

[illegible] – *Président: Hannah Briemberg (Vancouver, C.-B.)*

10h40 [illegible] .... *à déterminer*

11h [illegible] .... *David Cameron (Toronto, ON)*

11h20 [illegible] .... *Dean Foti (Vancouver, BC)*

11h40 [illegible] .... *Lorne Zinman (Toronto, ON)*

12h Séance de questions et réponses

12h15 Dîner

[illegible]

13h30 [illegible] – *Modérateur: à déterminer*

(1) [illegible] .... *Marife Fabros, Julia Higgins*

(2) [illegible] .... *à déterminer (C.-B. Provincial Respiratory Outreach Program)*

(3) [illegible] .... *à venir (Assistive Technologies Program [C.-B.])*

13h30 [illegible] – *Modérateur: Sanjay Kalra (Edmonton, AB)*

(1) [illegible] ..... *Hannah Briemberg (Vancouver, C.-B.)*

(2) [illegible] .... *John Turnbull (Hamilton, ON)*

15h Pause

[illegible] – *Présidents: David Cameron (Toronto, ON), représentant de l'ALSBC à déterminer*

15h15 [illegible] .... *Andy Eisen (Vancouver, C.-B.)*

15h45 Mot de la fin et formulaires d'évaluation .... *David Cameron (Toronto, ON), représentant de l'ALSBC à déterminer*

[illegible] *8h30-17h Crystal Ballroom, Empress*

[illegible]	Juliette Hukin, Asuri Prasad
[illegible]	À la fin de cette séance, 1) les participants sauront identifier les manifestations neurologiques des maladies enzymatiques chez les enfants 2) les participants sauront : i) distinguer les différents troubles métaboliques récemment découverts ii) intégrer les renseignements afin d'analyser et d'élaborer une approche clinique visant à sélectionner des essais en laboratoire appropriés sur les maladies enzymatiques à manifestations neurologiques iii) planifier et recommander un traitement neurologique approprié pour les patients qui souffrent de maladies enzymatiques.
[illegible]	neurologues, neuropédiatres, pédiatres, infirmières en neurosciences

8h30	[illegible] ... *Mark Tarnopolsky (Hamilton, ON))*
9h15	[illegible] ... *Miguel Cortez (Toronto, ON)*
9h55	[illegible] ... *Asuri N. Prasad (London, ON)*
10h40	Pause
10h55	[illegible] ... *Edward Kaye (Cambridge, MA, É-U)*
11h40	[illegible] ... *Chitra Prasad (London, ON)*
12h20	[illegible] ... *David Buckley (St. John's, NL)*
13h	Dîner
14h30	[illegible] ... *Sylvia Stockler (Vancouver, C.-B.)*
15h15	[illegible] ... *Edward Kaye, Asuri Prasad, Sylvia Stockler, Juliette Hukin*
16h15	Discussion et évaluation

[illegible] — *18h-20h Lecture Theatre, Conference Centre*

[illegible] Richard McLachlan

[illegible] le diagnostic de l'épilepsie se fonde sur la description d'événements paroxystiques. Ce cours vise à démontrer comment la vidéo peut être utilisée afin de documenter les crises épileptiques, de distinguer l'épilepsie des états non épileptiques et de classer les types de crises.

[illegible] À la fin de cette séance, les participants sauront :

1) distinguer différents types de crises au moyen de la vidéo
2) distinguer l'épilepsie des états non épileptiques
3) identifier les signes physiques d'un état de crise.

[illegible] résidents, moniteurs et étudiants en neurologie, neurologues pour adultes neuropédiatres, infirmières en neurologie et technologues en EEG

18h [illegible]................................ *Kevin Farrell (Vancouver, C.-B.)*
18h30 [illegible]................................ *Richard Desbiens (Québec, Québec)*
19h [illegible]................................ *à déterminer*
19h30 [illegible]................................ *Richard McLachlan (London, ON)*

[illegible] — *18h-20h Salle Oak Bay, Conference Centre*

Ce cours est rendu possible par une généreuse subvention éducative sans restriction de UCB Pharma

[illegible] Mandar Jog

[illegible] ce cours donne un aperçu des aspects pratiques du traitement dans le contexte du cabinet médical. Il sera question des symptômes communs mais peu reconnus de la maladie de Parkinson. Examen des problèmes psychiatriques vécus par les patients atteints de troubles du mouvement, surtout dans le cas de la maladie de Parkinson, de la maladie de Huntington et du syndrome de Gilles de La Tourette. Une séance vidéo sur les troubles rares du mouvement servira de conclusion à cette séance.

[illegible] À la fin de cette séance, les participants sauront :

1) traiter les symptômes non moteurs de la maladie de Parkinson
2) traiter les problèmes psychiatriques vécus par les patients atteints de troubles du mouvement
3) traiter les patients atteints de dystonie, de chorée et de myoclonie dans le contexte du cabinet médical
4) reconnaître certains troubles rares du mouvement.

[illegible] résidents, moniteurs, internistes, gériatres et neurologues.

18h [illegible]......... *Doug Hobson (Winnipeg, MB)*
18h25 [illegible]................................ *Alex Rajput (Saskatoon, SK)*
18h50 [illegible] .... *Kiran Rabherv (Vancouver, C.-B.)*
19h15 [illegible]................................ *Mandar Jog (London, ON)*
19h40 Discussion et évaluation

Victoria British Columbia

[illegible]

8h30-10h30 Lecture Theatre, Conference Centre

Ce cours est rendu possible par une généreuse subvention éducative sans restriction de Sanofi Aventis et de Bristol Myers Squibb.

[illegible] Andrew Kirk, Richard Desbiens

[illegible] À la fin de cette séance, les participants sauront :

1) comprendre
   a. l'utilisation actuelle et potentielle de la robotique.
   b. les progrès réalisés en matière de neuroimagerie depuis le début du 21e siècle.
2) connaître l'impact actuel et prévu des maladies vasculonerveuses au cours du 21e siècle.
3) acquérir une certaine compréhension du traitement des maladies lysosomales.

8h30 [illegible]

8h40 [illegible] .. *Garnette Sutherland (Calgary, AB)*

9h10 [illegible] ... *Antoine Hakim (Ottawa, ON)*

9h40 [illegible] .... *Edward Kaye (Cambridge, MA, É-U)*

[illegible]

10h45-12h15 Lecture Theatre, Conference Centre

[illegible] *12h30-14h Crystal Ballroom, Fairmont*

Cet événement est accrédité comme activité d'apprentissage collectif (Section 1) tel que définie par le programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada. Il a été élaboré conjointement par la Société canadienne de neurologie et Boehringer-Ingelheim (Canada) Ltd. Ce programme a été examiné et approuvé par la Société canadienne de neurologie pour l'obtention d'un crédit de niveau 1.

[illegible] *12h30-14h Salle Saanich, Conference Centre*

Cet événement est accrédité comme activité d'apprentissage collectif (Section 1) tel que définie par le programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada. Il a été élaboré conjointement par la Société canadienne de neurologie et Pfizer Canada Inc. Ce programme a été examiné et approuvé par la Société canadienne de neurologie pour l'obtention d'un crédit de niveau 1.

[illegible] *14h-17h30 Salle Sidney, Conference Centre*

[illegible]	Michael Tymianski
[illegible]	À la fin de cette séance, les participants sauront : 1) décrire les indications de traitement de la sténose carotidienne et de la maladie cérébrovasculaire occlusive intracrânienne. 2) décrire les différentes modalités de diagnostic qui existent pour le traitement de la sténose carotidienne et de la maladie cérébrovasculaire occlusive intracrânienne. 3) décrire les différentes modalités thérapeutiques qui existent pour le traitement de la sténose carotidienne et de la maladie cérébrovasculaire occlusive intracrânienne. 4) décrire le rythme de traitement, lorsque cela est approprié, de la sténose carotidienne et de la maladie cérébrovasculaire occlusive intracrânienne.
[illegible]	neurologues, neurochirurgiens, neuroradiologues, résidents, infirmières et membres du personnel paramédical.

14h	Introduction	*Michael Hill (Calgary, AB)*
14h05	[illegible]	*Ian Fleetwood (Halifax, Nouvelle-Écosse)*
14h40	Discussion	
14h55	[illegible]	*Stephen P. Lownie (London, ON)*
15h30	Discussion	
15h45	[illegible]	*Michael Tymianski (Toronto, ON)*
16h20	Discussion	
16h35	[illegible]	*Michael Hill (Calgary, AB)*
17h10	Discussion et évaluation	

[illegible] *14h-17h30 Lecture Theatre, Conference Centre*

[illegible]	Eric Massicotte
[illegible]	examiner les plus récents développements concernant les lésions médullaires traumatiques et non traumatiques.
[illegible]	Grâce à cette séance, les participants : 1) prendront connaissance des nouveaux développements en matière de recherche sur les lésions médullaires. 2) pourront comprendre les concepts liés à la recherche translationnelle. 3) pourront comprendre les différentes stratégies de recherche actuellement utilisées.
[illegible]	tous les professionnels des soins de santé en neuroscience

14h	[illegible]	*John Hurlbert (Calgary, AB)*
14h20	Discussion	
14h25	[illegible]	*Bradley Jacobs (Toronto, ON)*
14h45	Discussion	
14h50	[illegible]	*Steve Casha, (Calgary, AB)*
15h10	Discussion	
15h15	[illegible]	*Michael Fehlings (Toronto, ON)*
15h35	Discussion	
15h40	[illegible]	*Rob Brownstone (Halifax, Nouvelle-Écosse)*
16h	Discussion	
16h05	[illegible]	*Andre Krassiakov (Vancouver, C.-B.)*
16h35	Discussion	
16h40	[illegible]	*Eric Massicotte (Toronto, ON)*
17h	Discussion	
17h05	[illegible]	*Marcel Dvorak (Vancouver, C.-B.)*
17:25	Discussion et évaluation	

[illegible] *14h-17h30 Buckingham, Empress*

([illegible] Karel terBrugge

([illegible] les améliorations apportées à l'imagerie non invasive se sont traduites par des diagnostics plus rapides et plus précis des troubles vasculaires intracrâniens.

[illegible] À la fin de cette séance, les participants auront acquis des connaissances :

1) au sujet de l'imagerie contemporaine du système veineux intracrânien normal et de la maladie occlusive veineuse affectant le cerveau chez les adultes et les enfants.
2) au sujet des progrès récents réalisés en chirurgie à effraction minimale et en techniques d'intervention liées aux troubles vasculaires cérébraux.
3) quant à l'identification des différentes étiologies de la formation d'anévrismes et au choix de la modalité de traitement la plus appropriée à leur stratégie de traitement.
4) leur permettant de diagnostiquer et de sélectionner précisément les patients victimes de thrombose veineuse afin de leur offrir le meilleur traitement possible.

([illegible] neurochirurgiens, neuroradiologues et professionnels paramédicaux

14h [illegible] ..... *Gabrielle de Veber (Toronto, ON)*
14h20 [illegible] ..... *David Mikulis (Toronto, ON)*
14h40 [illegible] ..... *Mayank Goyal (Ottawa, ON)*
15h [illegible] ..... *Karel terbrugge (Toronto, ON)*
15h20 [illegible] ..... *Donatella Tampieri (Montreal, QC)*
15h40 Examens de cas et discussion ..... *Marlise de Santos (Ottawa, ON)*
16h Pause
16h30 [illegible] ..... *Ronit Agid (Toronto, ON)*
16h50 [illegible] ..... *Genevieve Milot (Québec, Québec)*
17h10 Examens de cas et discussion ..... *Marlise de Santos (Ottawa, ON)*

[illegible] *14h-17h30 Oak Bay 2, Conference Centre*

Ce cours est rendu possible par une généreuse subvention éducative sans restriction de Boehringer Ingelheim (Canada) Inc.

([illegible] Andrew Woolfenden, Andrew Penn

([illegible] le cours sur les accidents vasculaires cérébraux vise à fournir une mise à jour aux médecins quant aux progrès récents réalisés dans les domaines de la prévention des accidents vasculaires cérébraux et du traitement des accidents vasculaires cérébraux aigus.

[illegible] À la fin de cette séance, les participants sauront :

1) identifier les progrès récents réalisés dans le domaine du traitement des accidents vasculaires cérébraux.
2) choisir le traitement antiplaquettaire approprié pour la prévention des accidents vasculaires cérébraux.
3) comprendre le rôle joué par le traitement chirurgical des hémorragies intracérébrales et des accidents vasculaires cérébraux aigus.
4) comprendre l'utilité potentielle de l'imagerie avancée dans la thrombolyse destinée aux accidents vasculaires cérébraux.

([illegible] neurologues, neurologues spécialistes des accidents vasculaires cérébraux, neurochirurgiens, résidents en neurologie.

14h [illegible] .. *Greg Albers (Palo Alto, CA, É-U)*
14h30 [illegible] ..... *Ken Butcher (Edmonton, AB)*
14h45 Discussion
15h [illegible] ..... *Andrew Demchuk (Calgary, AB)*
15h20 Discussion
15h30 Pause
15h45 [illegible] ..... *Gary Redekop (Vancouver, C.-B.)*
16h05 Discussion
16h15 [illegible] ..... *Andrew Penn (Victoria, C.-B.)*
16h35 Discussion
16h45 [illegible] *Mike Sharma (Ottawa, ON)*
17h15 Discussion et évaluations

[illegible]

14h-17h30 Oak Bay 1, Conference Centre

Ce cours est rendu possible par une généreuse subvention éducative sans restriction d'UCB Pharma

[illegible] Mark Sadler, Taufik Valiante

[illegible] Ce cours d'une demi-journée est conçu pour fournir une mise à jour au sujet du diagnostic et du traitement des crises d'épilepsie dans des populations précises. Il portera sur les patients victimes d'une crise d'épilepsie pour la première fois, sur le traitement des problèmes découlant de l'épilepsie à l'adolescence, sur les crises psychogènes non épileptiques, sur les problèmes relatifs à l'épilepsie spécifiques aux femmes et sur le traitement chirurgical de l'épilepsie chez les patients atteints de tumeurs et de malformations vasculaires de faible degré de malignité.

[illegible] À la fin de cette séance, les participants sauront :

1) établir un algorithme servant au diagnostic et au traitement des patients qui souffrent d'une première crise d'épilepsie
2) identifier et gérer les problèmes liés à l'épilepsie et spécifiques à la population adolescente
3) anticiper et gérer les problèmes liés à l'épilepsie et spécifiques aux femmes
4) reconnaître et maîtriser les approches thérapeutiques s'adressant aux patients qui souffrent de crises psychogènes non épileptiques
5) élaborer un diagnostic et une approche thérapeutique s'adressant aux patients qui souffrent de crises

[illegible] neurologues œuvrant dans la communauté (adultes et enfants), neurologues et neurochirurgiens intéressés par l'épilepsie, professionnels paramédicaux travaillant dans des cliniques spécialisées en épilepsie.

14h [illegible] .... *Bernd Pohlmann-Eden (Halifax, Nouvelle-Écosse)*
14h30 Discussion
14h40 [illegible] .... *Peter Camfield (Halifax, Nouvelle-Écosse)*
15h10 Discussion
15h20 [illegible] .... *Danielle Andrade (Toronto, ON)*
15h50 Discussion
16h Pause
16h15 [illegible] .... *Elizabeth Donner, Sherese Ali (Toronto, ON)*
16h50 Discussion
17h05 [illegible] .... *Taufik Valiante (Toronto, ON)*
17h35 Discussion et évaluation

[illegible]

14h-17h30 Salle Esquimalt, Conference Centre

[illegible] Draga Jichici, Jeanne Teitelbaum

[illegible] À la fin de cette séance, grâce à des présentations de cas comprenant des cas pédiatriques et adultes, les participants :

1) acquerront des connaissances au sujet du diagnostic, de la gestion et du traitement des maladies infectieuses affectant le système nerveux et pouvant entraîner des maladies graves et mortelles du système nerveux central ainsi que des affections neuromusculaires
2) apprendront au moyen de présentations de cas comment améliorer un pronostic à la suite d'un arrêt cardiaque.

[illegible] neurologues praticiens, neurochirurgiens, résidents, infirmières, neurologues et neurochirurgiens pédiatriques, médecins du service des urgences, médecins des soins intensifs.

14h [illegible] .... *G. Bryan Young (London, ON)*
14h25 Discussion
14h30 [illegible] .... *Kesh Reddy (Hamilton, ON)*
14h55 Discussion
15h [illegible] .... *Charles Bolton (Kingston, ON)*
15h25 Discussion
15h30 Pause
15h45 [illegible] .... *Cecil Hahn (Toronto, ON)*
16h10 Discussion
16h15 [illegible] .... *Jeanne Teitelbaum (Montréal, Québec)*
16h40 Discussion
16h45 [illegible] .... *Draga Jichici (Hamilton, ON)*
17h10 Discussion et évaluation

[illegible] è [illegible] ; [illegible] & [illegible] & ([illegible] & [illegible] *8h30-10h Lecture Theatre, Conference Centre*

([illegible] Richard Desbiens

8h30 Accueil et introduction
8h40 [illegible] ..... *Peter Reickmann (Vancouver, C.-B.)*
9h20 [illegible] ..... *Warren Blume (London, ON)*

[illegible] è [illegible] ; [illegible] & [illegible] *8h30-10h Salle Saanich, Conference Centre*

Ce cours est rendu possible par une généreuse subvention éducative sans restriction de Medtronic du Canada

([illegible] Derek Fewer
[illegible] À la fin de cette séance, les participants :
1) auront acquis une compréhension plus approfondie de l'évolution naturelle et des solutions de traitement disponibles pour les patients souffrant de malformations artérioveineuses
2) comprendront l'incidence et le besoin de prévenir les lésions cérébrales et médullaires au Canada.

8h30 Accueil et introduction
8h35 [illegible] ..... *J.P. Mohr (New York, NY, É-U)*
9h20 [illegible] ..... *Charles Tator (Toronto, ON)*

[illegible] *10h15-12h30*

Neurochirurgie générale 1	*Lecture Theatre, Conference Centre*
Sclérose en plaques	*Salle Sidney, Conference Centre*
Neurologie des accidents vasculaires cérébraux	*Oak Bay 1, Conference Centre*
Neurologie générale 1	*Oak Bay 2, Conference Centre*
Chirurgie neurovasculaire	*Salle Esquimalt, Conference Centre*
Traumatismes et soins critiques	*Salle Saanich, Conference Centre*
Neuro-oncologie	*Salle Colwood, Conference Centre*

[illegible]

12h30-14h Carson Hall, Conference Centre

[illegible] *14h-16h30*

Neurochirurgie générale 2	*Lecture Theatre, Conference Centre*
Neurologie générale 2	*Salle Saanich, Conference Centre*
Colonne vertébrale	*Oak Bay 1, Conference Centre*
Neurovasculaire	*Oak Bay 2, Conference Centre*
Troubles du mouvement, neuromusculaire, démence	*Salle Esquimalt, Conference Centre*
Épilepsie	Salle Sidney, Conference Centre
Neurologie pédiatrique	Salle Colwood, Conference Centre

. [illegible] *16h30-17h30 Carson Hall, Conference Centre*

[illegible] — *8h30-9h30 Lecture Theatre, Conference Centre*

Ce cours est rendu possible par une généreuse subvention éducative sans restriction de la Fondation des sciences neurologiques du Canada

8h30 Accueil et introduction
8h40 [illegible] .... *Dennis Choi (Atlanta, GA, É-U)*

Dennis Choi

Nous sommes heureux de vous annoncer que le docteur Dennis Choi, vice-président exécutif pour la neuroscience chez Merck Research Labs et directeur général actuel de l'initiative de neuroscience de l'Université Emory, sera notre conférencier émérite invité. Le docteur Choi est membre en règle de l'Institute of Medicine et de son forum sur les neurosciences, du comité exécutif de la Dana Alliance for Brain Research (l'Alliance de Dana pour la recherche sur le cerveau) et du comité itinérant appuyant le programme HST de Harvard et du MIT. Il a par le passé siégé au conseil de la National Academy of Sciences sur les sciences de la vie, participé à de nombreux comités de rédaction (y compris en tant que membre du conseil de révision et de rédaction pour la revue Science et co-éditeur fondateur de la revue Neurobiology of Disease) et à des conseils consultatifs. Il a de plus été président de la Society for Neuroscience, président du comité national américain de l'Organisation internationale de recherche sur le cerveau et vice-président de l'American Neurological Association.

[illegible] — *9h30-9h45 Lecture Theatre, Conference Centre*

[illegible] — *9h30-9h45 Lecture Theatre, Conference Centre*

[illegible] — *9h45-10h15 Carson Hall, Conference Centre*

[illegible] — *10h15-12h Lecture Theatre, Conference Centre*

Ce cours est rendu possible par une généreuse subvention éducative sans restriction d'Allergan Inc.

[illegible] Michael Hill, Dean Johnston

[illegible] .... *à confirmer*
[illegible] .... *à confirmer*
[illegible] .... *à confirmer*

[illegible]

12h-13h30 Carson Hall, Conference Centre

Victoria British Columbia

[illegible] — *13h30-17h Salle Saanich, Conference Centre*

Ce cours est rendu possible par une généreuse subvention éducative sans restriction de Merck Frosst Canada Inc.

[illegible] Marek Gawel

[illegible] nouvelles observations au sujet de la migraine avec aura, de la céphalée trigéminale autonome et d'autres cas intéressants.

[illegible] À la fin de cette séance, les participants :

1. connaîtront les nouveaux aspects relatifs à la théorie sur la migraine avec aura.
2. connaîtront les plus récentes découvertes au sujet de la céphalée trigéminale autonome.
3. apprendront à identifier et à comprendre les céphalées secondaires.

[illegible] neurologues généralistes

13h30 Introduction ..... *Marek Gawel (Toronto, ON)*
13h45 [illegible] ..... *Werner Becker (Calgary, AB)*
14h05 Discussion
14h15 [illegible] ..... *Marek Gawel (Toronto, ON)*
14h35 Discussion
14h45 Pause
15h [illegible] ..... *Suzanne Christie (Ottawa, ON)*
15h20 Discussion
15h30 [illegible] ..... *Gordon Mackie (Richmond, C.-B.)*
15h50 Discussion
16h [illegible] ..... *Gordon Robinson (Vancouver, C.-B.)*
16h30 Discussion et évaluation générales

[illegible] — *13h30-17h Salle Oak Bay, Conference Centre*

[illegible] Christopher Honey

[illegible] ce cours servira à fournir aux neurochirurgiens et à leurs collègues une mise à jour quant aux informations les plus récentes concernant divers états neurochirurgiques communs et divers problèmes de traitement. Six conférenciers présenteront des informations scientifiques de base et les recommandations cliniques pertinentes en ce qui a trait aux éléments suivants : l'utilisation du suivi peropératoire et des disques artificiels dans le cadre du traitement des tumeurs cérébrales malignes, des séquelles de l'échec chirurgical rachidien, de l'hydrocéphalie et des accidents vasculaires cérébraux aigus.

[illegible] À la fin de cette séance, les participants pourront :

1. mieux évaluer l'utilité du suivi peropératoire,
2. mieux comprendre les avantages et les risques potentiels associés aux disques artificiels,
3. mieux traiter les patients atteints de tumeurs cérébrales malignes,
4. mieux traiter les patients souffrant d'hydrocéphalie,
5. mieux traiter les patients souffrant de séquelles de l'échec chirurgical rachidien,
6. mieux traiter les patients victimes d'accidents vasculaires cérébraux aigus.

[illegible] neurochirurgiens généralistes

13h30 [illegible] ..... *Ryojo Akagami (Vancouver, C.-B.)*
13h55 Discussion
14h [illegible] ..... *Walter Hader (Calgary, AB)*
14h25 Discussion
14h30 [illegible] ..... *Neil Duggal (London, ON)*
14h55 Discussion
15h [illegible] ..... *Ian Fleetwood (Halifax, Nouvelle-Écosse)*
15h25 Discussion
15h30 [illegible] ..... *Brian Toyota (Vancouver, C.-B.)*
15h55 Discussion
16h [illegible] ..... *Line Jacques (Montréal, Québec)*
16h25 Discussion et évaluation

[illegible]

13h30-17h Salle Esquimalt, Conference Centre

[illegible] Seyed Mirsattari

[illegible] À la fin de cette séance, les participants pourront :

1. mieux comprendre l'anatomie et l'histologie du cerveau en ce qui concerne l'épilepsie, plus particulièrement grâce à l'accent mis sur les connaissances actuelles en matière de connexion corticocorticale ou corticosubcorticale.
2. mieux connaître le potentiel de la membrane neuronale, les canaux ioniques, les jonctions lacunaires et les neurotransmetteurs excitateurs et inhibiteurs jouant un rôle dans l'épileptogénèse.
3. mieux comprendre la neurophysiologie cellulaire et les mécanismes de base de l'épileptogénèse.
4. mieux comprendre la neurophysiologie appliquée, grâce à une compréhension de base de l'EEG chezles humains.

[illegible] neurologues, neurochirurgiens, neuropédiatres et résidents en neurologie, en neurochirurgie et en neuropédiatrie.

13h30 [illegible] .... *John A. Keirnan (London, ON)*
14h15 Discussion
14h20 [illegible] .... *Michael Poulter (London, ON)*
14h55 Discussion
15h10 [illegible] .... *Brian R. Christie (Victoria, C.-B.)*
15h55 Discussion
16h [illegible] ...... *Michael Poulter (London, ON)*
16h45 Discussion et évaluation

[illegible]

13h30-17h Salle Colwood, Conference Centre

[illegible] Claude Martin

[illegible] forum de discussion sur les questions médico-légales pour les neurologues, les neurochirurgiens, les neuroradiologues et les avocats canadiens œuvrant dans ce domaine.

[illegible] À la fin de ce symposium, les participants sauront :

1) identifier deux comportements de pratique préventive visant à minimiser les risques de difficultés médico-légales.
2) élaborer deux stratégies visant à prévenir et, au besoin, servir de réponse aux événements défavorables dans les cas de neurologie et de neurochirurgie.
3) évaluer les implications médico-légales de situations cliniques liées à des cas de neurologie et de neurochirurgie.

[illegible] neurologues, neurochirurgiens et neuroradiologues praticiens du Canada.

13h30 [illegible] .... *William Tucker (Toronto, ON), Claude Martin, jr. (Ottawa, ON), Barbara J. Norell (Vancouver, C.-B.)*
13h50 Discussion
14h [illegible] .... *William Tucker, Claude Martin, jr., Barbara J. Norell*
14h20 Discussion
14h30 É[illegible] .... *William Tucker, Claude Martin, jr., Barbara J. Norell*
14h50 Discussion
15h É[illegible] .... *William Tucker, Claude Martin, jr., Barbara J. Norell*
15h30 Pause
15h45 [illegible] .... *William Tucker, Claude Martin, jr., Barbara J. Norell*
16h05 Discussion
16h15 Thèmes du symposium du panel : les thèmes suivants seront abordés en fonction du temps disponible :

- gérer un résultat imprévu
- comment se préparer à la découverte
- l'élaboration de lignes directrices cliniques
  - o à quel moment une nouvelle ligne directrice devient-elle « le standard idéal »?
  - o la portée médico-légale des politiques et des lignes directrices

16h45 Discussion et évaluation

[illegible] *13h30-17h Salle Sidney, Conference Centre*

Ce cours est rendu possible par une généreuse subvention éducative sans restriction de Pfizer Canada Inc.

([illegible] Howard Feldman

([illegible] ce cours sert de mise à jour au sujet de divers troubles démentiels et cognitifs rencontrés par les neurologues, les neurochirurgiens et les professionnels paramédicaux dans le cadre de leur pratique. Différents types de démence seront abordés, de la démence commune à la démence rare. Le cours mettra l'accent, entre autres, sur l'application de lignes directrices de pratique et sur l'intégration des progrès réalisés récemment en recherche sur les soins cliniques. Les directives canadiennes concernant le diagnostic et le traitement de la démence seront abordées, ainsi que les progrès réalisés dans le domaine de la démence frontotemporale, de la maladie à prions et du potentiel de l'immunothérapie, sur le point de devenir une solution de traitement importante pour les maladies neurodégénératives.

[illegible] À la fin de cette séance, les participants :

1. connaîtront les directives canadiennes concernant le diagnostic et le traitement de la démence et pourront les appliquer à leur pratique clinique.
2. comprendront la direction prise par la recherche thérapeutique actuelle en matière de démence neurodégénérative.
3. seront à jour quant aux divers types de démence, y compris les causes peu communes mais traitables.

([illegible] neurologues généralistes praticiens, neurochirurgiens, résidents, diplômés en neuroscience, infirmières en neurologie et neuropsychologues impliqués dans les évaluations cognitives.

13h30 Accueil et introduction du cours ..... *Howard Feldman (Vancouver, C.-B.)*

13h45 [illegible] ..... *Howard Chertkow (Montréal, Québec)*

14h05 Discussion

14h15 [illegible] ..... *Tiffany Chow (Toronto, ON)*

14h35 Discussion

14h45 [illegible] ..... *Howard Feldman (Vancouver, C.-B.)*

15h05 Discussion

15h15 Pause

15h30 [illegible] ..... *Gerard Jansen (Ottawa, ON)*

15h50 Discussion

16h [illegible] ..... *Neil Cashman (Vancouver, C.-B.)*

16h20 Discussion

16h30 [illegible] ..... *John Ringman (Los Angeles, CA, É-U)*

16h50 Discussion et évaluation

[illegible]	*13h30-17h Lecture Theatre, Conference Centre*

[illegible] Ashfaq Shuaib

[illegible] les progrès récents et les dernières mises à jour concernant le traitement des troubles neurologiques communs.

[illegible] À la fin de cette séance, les participants :

1. auront une idée précise des progrès récents réalisés dans le traitement de la myasthénie grave.
2. pourront mieux traiter leurs patients victimes d'accidents ischémiques transitoires.
3. pourront identifier les progrès récents réalisés dans l'évaluation et dans le traitement de l'épilepsie.
4. reconnaîtront et maîtriseront les approches thérapeutiques s'adressant aux patients qui souffrent de crises psychogènes non épileptiques.
5. pourront résumer les progrès récents réalisés dans le traitement de la sclérose en plaques.

[illegible] neurologues, neurochirurgiens, résidents et infirmières.

13h30 [illegible] .... *G. Bryan Young (London, ON)*
14h Discussion
14h10 [illegible] ....*Gregg Blevins (Edmonton, AB)*
14h40 Discussion
14h50 Pause
15h05 [illegible] .... *Zaeem Siddiqi (Edmonton, AB)*
15:35 Discussion
15h45 [illegible] .... *Ashfaq Shuaib (Edmonton, AB)*
16h10 Discussion
16h20 [illegible] .... *à déterminer*
16h50 Discussion et évaluation

[illegible]	*13h30-17h Crystal Ballroom, Empress*

Ce cours est rendu possible par une généreuse subvention éducative sans restriction de Talecris Biotherapeutics

[illegible]	Mike Nicolle
[illegible]	ce cours se compose d'une série de discussions sur des thèmes communs se rapportant aux maladies neuromusculaires et pertinents à la pratique de tous les jours. Une période est réservée à une discussion du public. Les discussions sont dirigées par des « experts » canadiens spécialisés en maladies neuromusculaires. Ce cours s'adresse aux résidents en neurologie et en physiatrie, aux neurologues communautaires et universitaires et aux physiatres. Les thèmes sont choisis en fonction des besoins des membres potentiels du public, obtenus au moyen d'une enquête envoyée par courriel ou par télécopieur. Les informations présentées comprennent des faits scientifiques cliniques de base sur la pathophysiologie des affections abordées.
[illegible]	À la fin de cette séance, les participants : 1) auront acquis une bonne connaissance des troubles communs affectant le système nerveux périphérique chez les personnes infectées par le VIH. 2) pourront diagnostiquer en toute confiance au moyen de leurs compétences cliniques et de tests de diagnostic appropriés des neuropathies des petites fibres, de façon à pouvoir élaborer une stratégie thérapeutique adéquate en vue du traitement 3) pourront élaborer une stratégie de diagnostic pour leurs patients atteints de neuropathie périphérique en se fondant sur des données cliniques et électrodiagnostiques. 4) pourront intégrer leurs connaissances au sujet des progrès récents réalisés dans le domaine des maladies neuromusculaires au traitement pratique de leurs patients atteints de ces maladies.
[illegible]	professionnels paramédicaux, résidents et moniteurs de neurologie et de physiatrie, neurologues universitaires et communautaires et physiatres intéressés par les domaines de la neurologie neuromusculaire et de la physiatrie, ou ayant un besoin de formation dans ce domaine.

13h30	[illegible] .... *Alister Prout (Vancouver, C.-B.)*
14h05	Discussion
14h15	[illegible] .... *John Stewart (North Vancouver, C.-B.)*
14h50	Discussion
15h	Pause
15h30	[illegible] .... *Ian Grant (Halifax, Nouvelle-Écosse)*
16h10	Discussion
16h15	[illegible] .... *Shannon L. Venance (London, ON)*
16h50	Discussion et évaluation